Scaffolds with stabilized MHC molecules for immune cell engineering

A stabilized MHC class I molecule with a disulfide bridge integrated into a polymer backbone addresses the inefficiencies of current aAPC scaffolds, enabling high-throughput production of T cells with high specificity and functionality for tumor regression or viral clearance.

JP7580754B2Active Publication Date: 2024-11-12DANMARKS TEKNISKE UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020570505
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-06-20
Filing Date
2019-06-19
Publication Date
2024-11-12
Estimated Expiration
2039-06-19

AI Technical Summary

Technical Problem

Current artificial antigen presenting cell (aAPC) scaffolds face challenges in efficiently expanding tumor-reactive T cells due to instability of MHC molecules, inefficient production methods, and the need for high-throughput platforms that can accommodate diverse antigenic peptides, leading to insufficient differentiation and functional capacity of T cells.

Method used

Development of a stabilized MHC class I molecule with a disulfide bridge linking the alpha-1 and alpha-2 domains, integrated into a polymer backbone, allowing for flexible assembly with cytokines and costimulatory molecules to create a scaffold that can be loaded with antigenic peptides, ensuring high specificity and functionality of T cell expansion.

Benefits of technology

The scaffold enables high-throughput production of quality-assured aAPC scaffolds that expand tumor-reactive T cells with high specificity and functionality, suitable for personalized immunotherapy protocols, overcoming the limitations of existing technologies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580754000001
    Figure 0007580754000001
  • Figure 0007580754000002
    Figure 0007580754000002
  • Figure 0007580754000003
    Figure 0007580754000003
Patent Text Reader

Abstract

The present invention relates to an artificial antigen-presenting cell (aAPC) scaffold for providing specific functional stimulation to cells to obtain ideal phenotypic and functional properties for mediating tumor regression or viral clearance. In particular, the scaffold of the present invention comprises stabilized MHC class I molecules without antigenic peptides. The scaffold can be loaded with antigenic peptides as needed to provide a rapid platform for effective proliferation and functional stimulation of specific T cells in a peptide-MHC targeted manner.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an artificial antigen presenting cell (aAPC) scaffold to provide specific functional stimulation to cells to obtain ideal phenotypic and functional properties to mediate tumor regression or viral clearance. In particular, the scaffold of the present invention comprises stabilized MHC class I molecules without antigenic peptides. The scaffold can be loaded with antigenic peptides on demand, providing a rapid platform for effective proliferation and functional stimulation of specific T cells in a peptide-MHC targeted manner. [Background technology]

[0002] Adoptive cell transfer (ACT), an immunotherapy approach in which tumor-reactive T cells from peripheral blood (PBMCs) or tumor-infiltrating lymphocytes (TILs) are extracted from patients, activated and expanded ex vivo, and then returned to the patient, has shown durable clinical responses in more than 50% of patients in melanoma studies. However, expansion of tumor-reactive T cells from PBMCs or TILs often requires extensive ex vivo culture at the expense of T cell differentiation and functional capacity. As a result, the transferred T cell product may not contain a sufficient frequency of tumor-reactive CD8 T cells with the appropriate phenotypic and functional characteristics to mediate tumor regression. Furthermore, the majority of such tumor-infiltrating T cells are not tumor-specific, but rather bystander infiltration of T cells from the periphery, whose T cell receptor (TCR) recognition may not match any tumor antigen. Finally, a fraction of tumor-reactive T cells may have reduced growth potential due to the suppressive environment present at the tumor site.

[0003] To overcome the problem of insufficient differentiation and functional capacity of expanded T cells, attempts have been made to utilize artificial antigen-presenting cells (aAPCs). The simple concept behind aAPCs is to mimic the natural interaction between TCR and specific antigenic peptides presented by the major histocompatibility complex (MHC). This interaction is a core step in the generation of immunity by activation, proliferation and differentiation of T cells that can elicit an efficient immune response. The natural generation of T cell responses is further supported by molecules that influence T cells, such as cytokines and costimulatory molecules, which serve to induce T cell activation and function. Thus, the incorporation of all the necessary molecules into a single aAPC scaffold is a promising tool to overcome some of the challenges of T cell expansion. aAPCs form an ideal immunological synapse for T cell activation and differentiation. However, a significant challenge is to identify the molecular combination that allows aAPCs to efficiently expand extracted TILs while also maintaining a functional phenotype.

[0004] WO2002072631 discloses many concepts that utilize MHC platforms, one of which is an MHC construct that includes one or more MHC-bound carrier molecules. The construct may also include biologically active molecules, such as costimulatory or cell regulatory molecules. It is contemplated that the MHC construct may be used, among other things, to expand cells that recognize the construct and to generate therapeutic compositions for use in treating diseases, such as cancer. WO2002072631 discloses many costimulatory molecules and cytokines that may be suitable for T cell expansion, but does not identify specific combinations that are particularly suitable and effective for T cell expansion.

[0005] US 2011 / 318380 discloses the application of MHC constructs described in WO 2002072631 for cancer vaccines and immune monitoring. However, US 2011 / 318380 does not exemplify specific combinations of costimulatory molecules and cytokines that are particularly suitable and effective for the expansion of T cells.

[0006] WO2009003492 focuses primarily on the detection of antigen-specific T cells, but also discloses the proliferation of antigen-specific T cells. MHC multimers with and without conjugated peptides, their preparation and their use in assays and therapies, including the isolation of antigen-specific T cells that can inactivate or eliminate unwanted target T cells, are described. MHC multimers according to WO2009003492 may include a dextrans scaffold as well as costimulatory and cell-regulatory molecules. However, the disclosure does not point out specific combinations of molecules that are particularly effective for the proliferation of T cells.

[0007] WO2009094273 discloses an aAPC composition containing nanoparticles, cytokines, coupling agents, T cell receptor activators and costimulatory molecules used to expand antigen-specific T cells. The T cell receptor activator can be an MHC molecule bound to an antigen peptide. Furthermore, the use of expanded T cells in adoptive immunotherapy is described. However, only the compatibility of a single cytokine, IL-2, on aAPC is investigated and compared to exogenous cytokines.

[0008] Thus, what is common to previous disclosures of aAPC scaffolds is that they only describe the concept in a mainly generic way. A well-defined and effective aAPC scaffold is highly required, since the success criteria of T cell expansion, i.e. high proportion of active T cells, high antigen specificity of T cells and high functionality of T cells, are only met when a specific combination of stimulatory molecules is combined. Only when all three success criteria for T cell expansion are met, the resulting T cell population is optimally prepared to apply their antitumor or antiviral functions.

[0009] Another limitation of known aAPC scaffolds is their inefficient and inflexible production, which is not in sync with the demand for high-throughput platforms to accelerate the development of new immunotherapies. A major obstacle in the preparation of aAPC scaffolds is caused by the requirement of MHC molecules for antigenic peptide presentation. Briefly, the refolding process of MHC molecules is complicated by the fact that the heavy chain cannot be folded to its native state in the absence of β2-microglobulin (B2M) and antigenic peptide. Thus, empty MHC class I molecules are highly unstable and prone to aggregation. Thus, every peptide-MHC combination desired for T cell stimulation requires an independent production line. This is problematic because the antigenic peptide landscape is very extensive, with an estimated range of 200,000 peptides efficiently presented per HLA molecule per patient, and the MHC class I molecules are highly diverse, with more than 12,000 known MHC class I molecules. Moreover, the selection of the appropriate antigenic peptide in a given situation depends on the disease of interest, the patient's MHC profile and the available T cell repertoire. Thus, a current single production line that can only generate one antigenic peptide-specific aAPC scaffold makes it virtually impossible to address the vast antigenic peptide diversity and the broad range of possible antigenic peptide and MHC molecule combinations that are addressed using conventional individualized aAPC production technologies.

[0010] Recombinant MHC class I molecules are produced, for example, in bacteria, to form insoluble inclusion bodies. Previously, these inclusion bodies are then denatured in a solution of a chaotropic agent, followed by removal of the chaotropic agent (e.g., by renaturation and refolding) in the presence of a specific antigen peptide of interest, resulting in the formation of pMHC complexes. The pMHC complexes are then purified from unfolded proteins by gel filtration chromatography. This is a laborious and relatively efficient technique that only produces one type of pMHC.

[0011] The inefficient production of MHC molecules has been attempted to be solved by the production of MHC molecules with intermediate peptides, which are replaced with the antigenic peptide of interest after refolding of the MHC molecule. This technique is known as MHC peptide exchange. However, the exchange rate is not 100%, and loss of exchangeable peptides can result in substantial (up to 50%) loss of MHC molecules that are not available for new peptide binding. Furthermore, this production method is time-consuming, and peptide exchange typically occurs at the MHC monomer stage, making the technology unsuitable for use with larger scaffolds. The above-mentioned limitations result in a lack of control over the stoichiometry of aAPC scaffold assembly, creating challenges associated with variable product stability depending on the pMHC molecules in place.

[0012] Yet another limitation of current aAPC scaffold technology that includes pMHC is the inherent instability of major histocompatibility complexes, which are known to have an antigenic peptide-dependent life span. The instability of pMHC limits the extent to which pMHC remains fully functional and therefore useful for assembling functional aAPC scaffolds. The instability of pMHC complexes also limits the time during which assembled aAPC complexes can remain fully functional and efficiently and antigen-specifically stimulate CD8 T cells.

[0013] In US Patent No. 9,494,588, providing empty MHC class I molecules that can be loaded with antigen peptides after folding of the MHC class I molecule is proposed as a convenient method to produce any antigen-specific MHC class I molecule from a single production line. However, whether this method is applicable for use in large aAPC scaffolds is merely speculation and has not been disclosed. For example, it has not been shown that they can interact with T cells with similar antigen-specific interaction properties as wt MHC molecules. Furthermore, it is unclear whether the introduced mutations can structurally affect the TCR-pMHC interaction. And similarly, the functionality of this modified interaction has not been described.

[0014] Therefore, an improved aAPC scaffold for high throughput setup would be advantageous, especially the provision of an aAPC scaffold that can be pre-produced and loaded with antigenic peptides on demand to expand and stimulate T cell populations, thereby resulting in a high proportion of active T cells, high antigen specificity of T cells and high functionality of T cells. Summary of the Invention

[0015] Therefore, an object of the present invention is to provide an artificial antigen presenting cell (aAPC) scaffold with improved capacity for the expansion of tumor-reactive T cells extracted from peripheral blood (PBMC) or tumor infiltrating lymphocytes (TIL).

[0016] Another object of the present invention is to provide a more user-friendly and high-throughput platform for generating large libraries of improved aAPCs presenting different antigenic peptides.

[0017] Moreover, the production of large batches of quality-assured aAPC scaffolds would better address the growing demands from regulatory authorities for quality assurance. Here, we can provide a “ready-to-go” solution to the production challenge with one large batch of quality-controlled aAPC scaffolds available for antigen peptide loading at the end user site. This would be an ideal solution for the growing number of highly personalized immunotherapy protocols in which patient tumors are sequenced to identify tumor mutations and predict cancer-specific peptide antigens. Such antigen peptides could be envisaged to be directly loaded into ready-made antigen peptide-receptive aAPC scaffolds.

[0018] In particular, it is an object of the present invention to provide an aAPC scaffold that overcomes the above-mentioned problems of the prior art of insufficient T cell differentiation and functional capacity of the expanded T cell population.

[0019] Another object of the present invention is to utilize the resulting expanded T cell populations with optimized phenotypic and functional properties to mediate tumor regression or viral clearance.

[0020] Thus, one aspect of the invention is a template molecule comprising: i. a molecule that affects at least one T cell; ii. at least one MHC class I molecule 1. An artificial antigen presenting cell (aAPC) scaffold comprising a polymer backbone having attached thereto The present invention relates to an artificial antigen presenting cell (aAPC) scaffold in which an MHC class I molecule comprises a heavy chain comprising an alpha-1 domain and an alpha-2 domain connected by a disulfide bridge.

[0021] Another aspect of the invention is a method for simultaneous in vitro stimulation and expansion of T cells, comprising the following steps: Providing a sample comprising iT cells; ii. contacting the sample with a proliferation solution comprising an aAPC scaffold according to the invention; iii. stimulating and expanding T cells with specificity for the aAPC scaffold in culture; iv. harvesting the T cells of step iii) from the culture to obtain a proliferated antigen-specific population of T cells; The present invention relates to a method comprising the steps of:

[0022] A further aspect of the invention provides an expanded T cell population obtainable by the method according to the invention.

[0023] Yet another aspect of the invention relates to an expanded T cell population obtained by the method according to the invention for use as a medicament.

[0024] Yet another aspect of the present invention is to provide an expanded T cell population obtainable by the method of the present invention for use in the treatment of cancer or viral disease.

[0025] A further aspect of the invention is a kit for expanding T cells comprising: i. a first storage means comprising at least one aAPC scaffold according to the invention; ii. a second storage means for at least one antigenic peptide; A kit comprising: The contents of the first storage means and the second storage means are adapted to be combined. [Brief description of the drawings]

[0026] [Figure 1]FIG. 1 shows (A) a schematic diagram of an exemplary artificial antigen presenting cell (aAPC) scaffold. The aAPC scaffold is composed of a scaffold to which template molecules, such as unloaded MHC class I molecules (or loaded peptide-MHC (pMHC) class I molecules) and molecules that influence T cells, such as cytokines or costimulatory molecules, are attached. Examples of aAPC scaffolds are given in which different ratios of scaffold and template molecules are assembled into the aAPC scaffold. (B) A diagram showing how carefully selected combinations of template molecules can be combined into the aAPC scaffold and used to expand specific T cell populations extracted from patients. [Diagram 2] FIG. 2 shows (A) the frequency of HLA-A1 FLU BP-VSD-specific CD8+ T cells from healthy donors detected directly ex vivo with PE (X-axis) and APC (Y-axis) labeled tetramers; (B) the frequency of HLA-A1 FLU BP-VSD-specific CD8+ T cells after 2 weeks of culture with either antigen-presenting scaffolds in a ratio of 1:10:5:5:5 (scaffold:pMHC:B7-2:IL-15:IL-21), (C) free FLU BP-VSD peptides, IL-15, and IL-21, or (D) antigen-presenting scaffolds in a ratio of 1:10:5:5:5 with irrelevant peptide specificity, with 20 IU / ml IL-2 added in the culture medium; (E) the frequency of HLA-A1 FLU BP-VSD-specific CD8+ T cells detected by tetramer staining using baseline and from 1 and 2 weeks after expansion. (F) The expansion rate based on the frequency of BP-VSD-specific CD8+ T cells, and (F) the absolute number of HLA-A1 FLU BP-VSD-specific CD8+ T cells after 2 weeks of expansion. [Diagram 3]3 shows dot plots of TNF-α and IFN-γ expression among CD8 T cells after stimulation with HLA-A*02:01, FLU 58-66 GILGFVFTL peptide (SEQ ID NO: 20) comparing the functionality of CD8 T cells expanded using aAPC scaffolds assembled with Cys-mutants and wild-type MHC molecules. HLA-A*02:01, FLU 58-66 GILGFVFTL-specific CD8 T cells with an initial frequency of 0.3% (left, pre-expansion pMHC dual color tetramer staining plot) from healthy donor PBMCs were expanded for 10 days using aAPC scaffolds assembled in a ratio of 1:8:8:8 (scaffold:pMHC:IL-2:IL-21) and stimulated with FLU 58-66 GILGFVFTL peptide. An aAPC scaffold with irrelevant peptide (HLA-A*02:01 HIV Pol ILKEPVHGV (SEQ ID NO: 23)) specificity and used in expansion cultures followed by peptide stimulation was used as a negative control. The TNF-α antibody is PE-Cy7 labeled (Y-axis) and the IFN-γ antibody is APC labeled (X-axis). These stainings were performed in duplicate, but only one of each staining is shown. [Figure 4]4 shows dot plots of TNF-α and IFN-γ expression among CD8 T cells after stimulation with HLA-A*02:01, EBV BMF1 GLCTLVAML peptide (SEQ ID NO: 21) comparing the functionality of CD8 T cells expanded using aAPC scaffolds assembled with Cys-mutants and wild-type MHC molecules. HLA-A*02:01, EBV BMF1 GLCTLVAML-specific CD8 T cells with an initial frequency of 0.05% obtained from healthy donor PBMC (left, before expansion, pMHC dual color tetramer staining plot) were expanded for 10 days using aAPC scaffolds assembled with a ratio of 1:8:8:8 (scaffold:pMHC:IL-2:IL-21) and stimulated with EBV BMF1 GLCTLVAML peptide. An aAPC scaffold with irrelevant peptide (HLA-A*02:01 HIV Pol ILKEPVHGV (SEQ ID NO: 23)) specificity and used in expansion cultures followed by peptide stimulation was used as a negative control. The TNF-α antibody is PE-Cy7 labeled (Y-axis) and the IFN-γ antibody is APC labeled (X-axis). These stains were performed in duplicate, but only one of each stain is shown. [Diagram 5]Figure 5 shows tetramer staining dot plots of HLA-A*02:01 CMV pp65 NLVP MVATV (SEQ ID NO: 22)-specific CD8 T cells grown using aAPC scaffolds, comparing the growth efficiency of post-assembly Cys-mutant MHC (i.e., loadable) aAPC scaffolds with pre-antigen-loaded assembly of the scaffolds (Cys-mutant or wild-type MHC). Figure 5A, Baseline frequency of HLA-A*02:01 CMV pp65 NLVP MVATV-specific CD8 T cells (expressed as % of total CD8 T cells as determined by pMHC-specific double positive tetramer). FIG. 5B compares HLA-A*02:01 CMV pp65 NLVPMV ATV-specific CD8 T cells grown for 10 days and quantified using pMHC-specific PE tetramers across preassembled peptide-antigen aAPCs loaded with Cys-mutant MHC, preloaded aAPCs with Cys-mutant MHC, and preloaded aAPCs with wild-type MHC. [Figure 6] 6 shows dot plots depicting expression of TNF-α and IFN-γ among CD8 T cells following stimulation with HLA-A*02:01, CMV pp65 NLVPMVATV peptide (SEQ ID NO:22), comparing the functionality of CD8 T cells grown on aAPC scaffolds assembled with post-assembly peptide-antigen aAPCs loaded with Cys-mutated MHC, preloaded aAPCs with Cys-mutated MHC, and preloaded aAPCs with wild-type MHC. TNF-α antibody is PE-Cy7 labeled (Y-axis) and IFN-γ antibody is APC labeled (X-axis). These stains were performed in duplicate, but only one of each stain is shown. [Figure 7]Figure 7 shows dot plots of TNF-α and IFN-γ double positive CD8 T cells after stimulation with HLA-A*02:01, EBV BMF1 GLCTLVAML peptide (SEQ ID NO: 21). HLA-A*02:01, EBV BMF1 GLCTLVAML specific CD8 T cells from healthy donor PBMC were expanded for 10 days using aAPC scaffold 1:8:8:8 (scaffold:MHC / pMHC:IL-2:IL-21) to compare the functionality of expanded CD8 T cells across aAPC scaffolds assembled with post-assembly peptide-antigen aAPC loaded with Cys-mutated MHC, preloaded aAPC with Cys-mutated MHC, and preloaded aAPC with wild-type MHC (Figure 7B). TNF-α antibody is PE-Cy7 labeled (Y-axis) and IFN-γ antibody is APC labeled (X-axis). These stains were performed in duplicate, but only one of each stain is shown. Baseline HLA-A*02:01, EBV BMF1 GLCTLVAML-specific CD8 T cells in donor PBMCs were measured by pMHC-specific dual color tetramer and are shown as % of total CD8 T cells (Figure 7A). [Figure 8] Figure 8 shows dot plots of flow cytometry analysis comparing TCR recognition of HLA-A*02:01 antigen-specific CD8 T cells using pMHC tetramers prepared with wt MHC (top panel) or Cys-mutated pMHC tetramers (bottom panel). Four different antigen specificities are analyzed to demonstrate that Cys-mutated MHC recognizes CD8 T cell TCR in a manner comparable to wt MHC. CD8 positive T cells are expressed as a percentage of total CD8 T cells and detected in two colors, hence the double positive dot plot (X and Y axis). [Figure 9]Figure 9 shows the proliferation of CD8 T cells after stimulation with HLA-A*01:01 CMV pp65 YSEHPTFTSQY peptide (SEQ ID NO: 30). (A) Identification of HLA-A*01:01 CMV pp65 YSEHPTFTSQY-specific CD8 T cells from peripheral blood using MHC tetramers labeled with fluorescent markers PE and BV605, respectively. Plots pre-targeted CD8 T cells. (B) Population of HLA-A*01:01 CMV pp65 YSEHPTFTSQY-specific CD8 T cells after 2 weeks of expansion using neo2 / 15+pMHC Ag scaffold. Shown are CD8 T cells (y-axis) and MHC tetramer positive T cells labeled BV605 (x-axis). The population is enhanced from 0.6% HLA-A*01:01 CMV pp65 YSEHPTFTSQY-specific CD8 T cells to 8.4% of total CD8 T cells before expansion. (C) Ability of HLA-A*01:01 CMV pp65 YSEHPTFTSQY-specific CD8 T cells to respond to antigen exposure. 40% of total T cells respond with multicytokine secretion.

[0027] The invention is described in further detail below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] definition Before discussing the present invention in more detail, the following terms and expressions will first be defined: Artificial antigen presenting cell (aAPC) scaffold In this context, the term "artificial antigen presenting cell (aAPC) scaffold" refers to an assembly of the necessary molecules as defined herein to function similarly to an antigen presenting cell.

[0029] Polymer Backbone In this context, the term "polymer backbone" refers to the portion of the aAPC scaffold onto which the individual template molecules are immobilized. The template molecules are attached by interactions between a coupling agent located on the polymer backbone or as an integral part of the polymer backbone and an affinity tag located on the template molecule. Alternatively, the coupling agent can be on the template molecule and the corresponding affinity tag can be on the polymer backbone.

[0030] The polymer backbone may be of a material selected from polysaccharides, vinyl polymers, polyethylene glycol, polypropylene glycol, strep-tactin, poly-streptavidin, biotin-binding proteins and polyhistidine-binding polymers.

[0031] Template molecule In this context, the term "template molecule" refers to any molecule that is attached onto the polymer backbone of the aAPC scaffold. They can be selected from MHC class I molecules, molecules that influence T cells, such as cytokines and costimulatory molecules, and CD47. Template molecules include affinity tags.

[0032] In some embodiments, the template molecule can be attached directly to the solid support rather than onto a polymer backbone.

[0033] Molecules that affect T cells In this context, the term "molecule that affects T cells" refers to any molecule that has a biological effect on T cells, including but not limited to proliferation, differentiation and stimulation of T cells.

[0034] Thus, molecules that affect T cells can be utilized to expand and functionally manipulate T cell populations to obtain desired differentiation resulting in high specificity, high killing capacity, high in vivo proliferation and survival characteristics. Molecules that affect T cells include, but are not limited to, cytokines, costimulatory molecules, and adhesion molecules.

[0035] An aAPC scaffold of the invention can comprise molecules that affect one or more different types of T cells, for example, molecules that affect at least 1, at least 2, at least 3, at least 4, or at least 5 different types of T cells.

[0036] Furthermore, the number of T cell influencing molecules located on each aAPC can be one or more and can vary depending on the design of the aAPC. Thus, the number of T cell influencing molecules on an aAPC scaffold can be in the range of 1-100, such as 1-50, such as 1-25, such as 1-20, such as 1-15, such as 1-10, or such as 1-5.

[0037] Mutated cysteine ​​residue In this context, the term "mutated cysteine ​​residue" refers to a cysteine ​​residue that has been artificially introduced into the heavy chain of an MHC class I molecule, and is therefore not present in the heavy chain of the corresponding wild-type MHC class I molecule.

[0038] The mutated cysteine ​​residue can be introduced by mutagenesis techniques known to those skilled in the art, such as site-directed mutagenesis.

[0039] non-covalent interactions In this context, the term "non-covalent interaction" refers to any bond through interactions other than covalent bonds. Non-covalent bonds can be formed, for example, by hydrophobic interactions, hydrophilic interactions, ionic interactions, van der Waals forces, hydrogen bonds, and combinations thereof.

[0040] Coupling Agent In this context, the term "coupling agent" refers to a molecular entity located on the polymer backbone of the aAPC. The coupling agent can non-covalently bind to the affinity tag. Examples of coupling agents include streptavidin, avidin, strep-tactin, antibodies, polyHis-tags, metal ion chelates, etc.

[0041] Alternatively, the coupling agent can be on the template molecule and the corresponding affinity tag can be on the polymer backbone.

[0042] Affinity Tags In this context, the term "affinity tag" refers to a molecular species located on a template molecule. Affinity tags bind highly specifically to coupling agents through non-covalent interactions. Examples of coupling agents include biotin, antibody epitopes, His-tags, streptavidin, strep-tactin, polyhistidine, peptides, metal ion chelates, etc.

[0043] Alternatively, the affinity tag can be on the polymer backbone and the corresponding coupling agent can be on the backbone of the template molecule.

[0044] Antigenic peptides In this context, the term "antigenic peptide" refers to a peptide that can bind to a major histocompatibility complex (MHC) molecule to form a peptide-MHC (pMHC) complex that can present the antigenic peptide to immune cells to induce a T cell receptor-dependent immune response.

[0045] The MHC may be an MHC class I molecule.

[0046] MHC In this context, the term "MHC" refers to the major histocompatibility complex, a protein complex whose primary function is to bind antigenic peptides derived from pathogens and present them on the cell surface for recognition by appropriate T cells.

[0047] There are two main classes of MHC molecules: MHC class I molecules and MHC class II molecules. As used herein, "MHC" refers to MHC class I molecules. MHC class I molecules are composed of an α chain (heavy chain) produced by the MHC gene and a β chain (light chain or β2-microglobulin) produced by the β2-microglobulin gene.

[0048] The heavy chains are composed of three domains, designated α-1, α-2 and α-3, respectively. The α-1 domain is located next to non-covalently bound β2-microglobulin. The α-3 domain is a transmembrane domain that anchors the MHC class I molecule in the cell membrane. Together, the α-1 and α-2 domains form a heterodimer that contains a peptide-binding groove that binds specific antigenic peptides. The amino acid sequence of the peptide-binding groove is the determining factor for which specific antigenic peptide will bind to the MHC class I molecule.

[0049] Of course, the heavy chain of MHC class I molecules contains four conserved cysteine ​​residues, resulting in the formation of two disulfide bridges: in the correctly folded conformation of MHC class I molecules, one disulfide bridge is located within the α-2 domain between Cys101 and Cys164, and another disulfide bridge is located within the α-3 domain between Cys203 and Cys259; the amino acid numbering refers to HLA-A without the signal peptide.

[0050] In the present invention, an additional disulfide bridge is introduced by recombinantly introducing two cysteine ​​residues between the alpha-1 and alpha-2 domains. Preferably, the two mutated cysteines are introduced at positions in the heavy chain where the spatial distance between the cysteine ​​residues in the alpha-1 and alpha-2 domains is between 2 and 10 Å.

[0051] MHC molecules can be either empty or bound to an antigenic peptide. Thus, in this context, a distinction is made between MHC molecules without an antigenic peptide (i.e. empty MHC molecules) and pMHC molecules, which refer to MHC molecules with bound antigenic peptides.

[0052] In this context, the terms "loadable aAPC scaffold", "antigenic peptide-receptive aAPC scaffold" and "empty aAPC scaffold" are used interchangeably and refer to an aAPC scaffold having MHC molecules without antigenic peptide.

[0053] In humans, the MHC complex is encoded by the human leukocyte antigen (HLA) gene complex. Thus, in this context, the term "MHC" also encompasses "HLA". There are three major types of HLA, and therefore, in this context, MHC includes, but is not limited to, HLA alleles encoded at the HLA-A, HLA-B, and HLA-C loci. Similarly, MHC includes, but is not limited to, MHC class I-like molecules, such as HLA-E, HLA-F, HLA-G, HLA-H, MIC A, MIC B, CD1d, ULBP-1, ULBP-2, and ULBP-3.

[0054] pMHC In this context, the term "pMHC" refers to an MHC molecule as defined above to which an antigenic peptide binds. The term pMHC therefore refers to an MHC class I molecule loaded with an antigenic peptide.

[0055] Cytokines In this context, the term "cytokine" refers to immunoregulatory molecules that affect the proliferation, survival and effector functions of stimulated T cells. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.

[0056] Examples of interleukins include, but are not limited to, IL-21, IL-2, IL-15, IL-1, IL-4, IL-6, IL-7, IL-9, IL-10, IL-12, IL-17, IL-22, and IL-23. Cytokines also include variants or mimetics of interleukins that induce T cell stimulation and activation corresponding to one or more interleukins. Variants or mimetics of interleukins may contain the binding site of the native cytokine, but the remainder of the protein may vary. Thus, variants or mimetics of interleukins include, but are not limited to, variants of IL-2, IL-15, and IL-21, or combinations thereof, such as IL-2 / IL-15.

[0057] A particular interleukin mutant or mimic within the cytokine family is termed neoleukin-2 / 15. Neoleukin-2 / 15 (Neo-2 / 15) is a highly stable designer cytokine that binds potently to IL-2Rβγc but not to CD25.

[0058] Cytokine Gamma Chain Receptor In this context, the term "γ-chain receptor cytokine" refers to a group of cytokines that bind to corresponding cytokine receptors that contain a common γ-chain subunit. c The γ-chain receptor cytokines are also known as CD132 or interleukin-2 receptor subunit gamma (IL-2RG). One thing that γ-chain receptor cytokines have in common is that they all deliver their intracellular signals through a shared γ-chain receptor to affect T cell activation and differentiation.

[0059] Gamma c Glycoproteins are transmembrane proteins that contain extracellular, transmembrane and intracellular domains and are typically expressed on lymphocytes. cThe subunits are part of the receptor complexes of at least six different cytokine receptors, namely, the IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors. Thus, the group of gamma chain receptor cytokines includes at least IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Gamma chain receptor cytokines also include variants or mimetics of gamma chain receptor cytokines that induce T cell stimulation and activation in response to one or more interleukins, such as IL-2, IL-15 and IL-21, or combinations thereof, such as variants of IL-2 / IL-15.

[0060] costimulatory molecules In this context, the term "costimulatory molecule" refers to a molecule that, upon interaction with a T cell, enhances T cell response, proliferation, production and / or secretion of cytokines, stimulates T cell differentiation and effector function, or promotes T cell survival compared to a T cell not contacted with the costimulatory molecule. Examples of costimulatory molecules include, but are not limited to, B7.1, B7.2, ICOS, PD-L1, a-galactosylceramide, CD3, CD4, CD5, CD8, CD9, CD27, CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM), CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), Fas (CD95), CD40, CD48, CD70, and CD72.

[0061] adhesion molecules In this context, the term "adhesion molecules" refers to molecules that induce adhesion between the aAPC scaffold and T cells, including, but not limited to, ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-LFA-2 (CD2), LFA-3 (CD58), anti-CD44, anti-beta-7, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

[0062] Epitope In this context, the term "epitope" refers to an antigenic determinant recognized by the TCR of a T cell. The epitope presented by pMHC is highly specific for any foreign substance and its interaction with the TCR ensures efficient proliferation and functional stimulation of specific T cells in a peptide-MHC targeted manner.

[0063] solid support In this context, the term "solid support" refers to any type of insoluble material to which an aAPC scaffold can be attached. The aAPC scaffold can be covalently or reversibly attached to the solid support. The aAPC scaffold attached to the solid support can be easily separated from excess reagents or solvents (e.g., by filtration, chromatography, centrifugation, etc.).

[0064] Solid supports include, but are not limited to, beads, well plates, particles, filters, gels, tubes, and petri dishes.

[0065] In some embodiments of the invention, the template molecules, ie, T cell-influencing molecules and MHC class I molecules, can be directly bound to a solid support.

[0066] sample In this context, the term "sample" refers to a solution extracted from a subject, the solution containing a population of T cells. The sample is not limited to any particular source and can be extracted, for example, from blood, tissue or bodily fluids. The T cell population can contain T cells with different specificities.

[0067] Growth solution In this context, the term "expansion solution" refers to a solution comprising an aAPC scaffold for use in expanding T cells having specificity for aAPC. The expansion solution may further comprise other entities that support the proliferation, differentiation and stimulation of T cells, for example, the expansion solution may comprise additional cytokines, co-stimulatory molecules or adhesion molecules in addition to those immobilized on the aAPC scaffold.

[0068] Clinically relevant numbers In this context, the term "clinically relevant number" refers to the number of cells required to combat the disease. The absolute clinically relevant number of cells varies depending on the disease. The number of cells available before being reintroduced into the patient is about 10 per dose. 5 ~10 12 cells per dose, e.g., 10 5 ~10 10 cells, e.g., 10 per dose 6 ~10 9 The range may be within a single cell.

[0069] Pharmaceutical Compositions In this context, the term "pharmaceutical composition" refers to a composition obtained according to the present invention comprising an expanded T cell population suspended in a suitable amount of a pharma- ceutically acceptable diluent or excipient and / or a pharma- ceutically acceptable carrier.

[0070] Pharmaceutically acceptable In this context, the term "pharmaceutical acceptable" refers to molecular entities and compositions that are physiologically tolerable and that, when administered to humans, typically do not produce allergic or similar adverse reactions, e.g., hyperactivity, dizziness, etc. Preferably, as used herein, the term "pharmaceutical acceptable" means approved by a federal or state government regulatory agency or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more particularly in humans.

[0071] Adjuvants In this context, the term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. Adjuvants can act as tissue depots that slowly release antigens and as lymphatic system activators, which can nonspecifically enhance the immune response. In many cases, primary challenge with an antigen alone, in the absence of an adjuvant, does not elicit a humoral or cellular immune response. Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surfactants such as lysolecithin, Pluronic® polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacilli Calmette-Guerin) and Corynebacterium parvum. Preferably, the adjuvant is pharma- ceutical acceptable.

[0072] Excipients In this context, the term "excipient" refers to a diluent, adjuvant, carrier, or vehicle with which the composition of the present invention is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or aqueous solutions, saline solutions, and aqueous dextrose and glycerol solutions are used as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.

[0073] Sequence identity In this context, the term "sequence identity" is defined herein as sequence identity between genes or proteins at the nucleotide, base or amino acid level, respectively. Specifically, DNA and RNA sequences are considered to be the same if the transcription product of the DNA sequence can be transcribed into the same RNA sequence.

[0074] Thus, "sequence identity" in this context is a measure of identity between proteins at the amino acid level and between nucleic acids at the nucleotide level. Protein sequence identity can be determined by comparing the amino acid sequence at a given position in each sequence when the sequences are aligned. Similarly, nucleic acid sequence identity can be determined by comparing the nucleotide sequence at a given position in each sequence when the sequences are aligned.

[0075] To determine the percent identity of two amino acid sequences or two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced into the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions (e.g., overlapping positions) x 100). In one embodiment, the two sequences are the same length.

[0076] In another embodiment, the two sequences are of different lengths and the gaps are seen as different positions. The sequences can be manually aligned and the number of identical amino acids counted. Alternatively, the alignment of two sequences for the determination of percent identity can be achieved using a mathematical algorithm. Such an algorithm is incorporated in the NBLAST and XBLAST programs of (Altschul et al. 1990). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences that are homologous to the nucleic acid molecules of the present invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences that are homologous to the protein molecules of the present invention.

[0077] Gapped BLAST can be used to obtain gapped alignments for comparison purposes. Alternatively, PSI-Blast can be used to perform an iterative search to detect distant relationships between molecules. When using NBLAST, XBLAST, and Gapped BLAST programs, the default parameters of each program can be used. See http: / / www.ncbi.nlm.nih.gov. Alternatively, sequence identity can be calculated after aligning sequences, for example, with the BLAST program of the EMBL database (www.ncbi.nlm.gov / cgi-bin / BLAST). Generally, default settings, for example, for "scoring matrix" and "gap penalty", can be used for alignment. In the context of the present invention, BLASTN and PSI BLAST default settings can be advantageous.

[0078] The percent identity between two sequences can be determined using techniques similar to those described above, with or without gaps allowed. In calculating percent identity, only exact matches are counted. Thus, embodiments of the present invention relate to sequences of the present invention having some degree of sequence variation.

[0079] aAPC scaffolds with stabilized MHC class I molecules T cells play a key role in the immune response, recognizing and responding to foreign substances by interacting with antigen-presenting cells (APCs) and presenting antigenic peptides of the foreign substances in complex with MHC molecules (pMHC). T cells are highly specific, expressing only a single specificity of T cell receptor (TCR), thereby enabling the T cell to recognize and respond only to a single specificity pMHC molecule. Once T cells are first primed to develop receptors for a specific combination of antigen and MHC molecule, they are subsequently unable to recognize other specificities. This specialization of T cells is called MHC restriction and can be exploited to expand monospecific T cells free of irrelevant specificities that "contaminate" the expanding T cell population.

[0080] MHC molecules exist in several variants, of which MHC class I and MHC class II molecules may be considered the most important. MHC class I molecules interact with CD8 positive cytotoxic T cells (CD8+ T cells) and MHC class II molecules interact with CD4 positive helper T cells (CD4+ T cells). Once activated, CD8+ T cells generally attempt to kill cancer cells, cells infected (especially with viruses), cells characterized by overexpressed cancer antigens, cells expressing mutations, i.e. neoantigens, cancer-testis antigens, or cells that are otherwise damaged. On the other hand, CD4+ T cells function primarily by supporting the immune system, for example by releasing cytokines, enhancing CD8+ T cells. Although not limited to a single type of T cell, the present invention is primarily concerned with the activation, stimulation, and proliferation of CD8+ T cells. This is particularly true since the use of aAPC scaffolds plays to some extent the integrated role of CD4+ T cells and antigen presenting cells.

[0081] Although TCR-pMHC interaction is the main driving force for T cell activation, several other factors are required to prepare T cells for an effective immune response. Overall, activation of CD8+ T cells requires two signals; 1) the interaction between TCR and pMHC class I molecules, and 2) the costimulatory interaction between CD28, a membrane receptor on T cells, and CD28 ligands located on APCs, such as B7.1 (CD80) or B7.2 (CD86). The second signal serves to enhance proliferation, cytokine production, and cell survival.

[0082] In addition to stimulatory signals, T cell responses are also regulated by inhibitory signals. Tim-3, LAG-3 and PD-1 are examples of mediators of inhibitory signals. They serve as a natural mechanism to avoid excessive T cell activation and prevent the immune system from spreading throughout the organism.

[0083] Secondary signals can be supported or possibly replaced by stimulation of CD8+ T cells with cytokines released by CD4+ T cells. Thus, cytokines constitute another important group of molecules involved in the regulation of immune responses. Cytokines generally include interleukins, interferons, chemokines, lymphokines, and tumor necrosis factors. They act through receptors and regulate, among other things, the maturation, growth, and responsiveness of T cell populations. Taken together, interleukin-2 (IL-2) and costimulatory signals are the most important factors for the preservation of successive cell divisions. The delicate interplay between costimulatory molecules and cytokines is complex and is one of the key factors for efficient and specific T cell proliferation.

[0084] Another molecule that plays an important role not only in immune responses but also in cellular processes such as apoptosis, proliferation, adhesion, and migration is CD47. This transmembrane protein is ubiquitously expressed in human cells, but is overexpressed in a wide variety of tumor cells, and high levels of CD47 allow cancer cells to avoid phagocytosis. However, CD47 is also widely expressed in immune cells and functions as a "don't eat me" signal that extends the circulation time of immune cells. Expansion of CD47-expressing T cells may be favorable, as it is expected to increase half-life when these cells are used therapeutically.

[0085] Thus, an embodiment of the invention relates to an aAPC scaffold as described herein, wherein the template molecule comprises a ligand capable of stimulating CD47 expression in a T cell population.

[0086] CD47 may also be a beneficial property for the aAPC itself, for example, as a "don't eat me" signal that extends the half-life of the aAPC scaffold in culture or in the circulation.

[0087] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, further comprising CD47.

[0088] As exemplified above, there are many factors involved in the activation and proliferation of T cells. However, for immunotherapy and / or the expansion of specific T cell populations, it is possible to set certain conditions that should ideally be met in order to provide the T cell population with high activity and functionality suitable for these purposes. Thus, preferred properties of expanded T cells include: a. High expression of activators (e.g. CD28) b. Low expression of inhibitors (e.g. PD1) c. Polyfunctional, i.e., simultaneous secretion of several cytokines.

[0089] Clusters of different molecules required for efficient activation and stimulation must be present simultaneously to provide optimal capacity for T cell function and proliferation. The use of aAPC scaffolds brings together combinations of the required molecules in defined proximity to each other, thus constituting a suitable platform for efficient proliferation of specific T cells.

[0090] The prospect of utilizing aAPC scaffolds for efficient expansion of highly specialized and active T cells is very promising. However, there remains a challenge to transform technologies based on MHC antigen presentation into truly high-throughput platforms. This is because refolding of MHC molecules is not possible in the absence of antigen peptides, and their production is therefore complicated and expensive. Not only are there thousands of MHC class I allotypes, but a new individualized aAPC scaffold must be produced for each antigen peptide to be tested or utilized for therapeutic purposes. It is more efficient and flexible to produce MHC molecules without antigen peptides, and instead add antigen peptides just before assembling the aAPC scaffold as needed. It is even more effective and flexible to produce a fully assembled aAPC scaffold using MHC molecules without antigen peptides, and instead add antigen peptides as needed.

[0091] Thus, to provide a high throughput platform for the expansion of T cells and the development of new immunotherapies, the aAPC scaffold of the invention may be equipped with an empty MHC class I molecule to which antigenic peptides can be added after production of the aAPC scaffold. The MHC class I molecule is stabilized by the artificial introduction of a disulfide bridge linking the alpha-1 and alpha-2 domains of the heavy chain. The disulfide bridge is located outside the peptide binding groove at the distal end of the C-terminal peptide binding pocket. Such structural changes in the MHC class I molecule mimic the conformational and dynamic effects of a bound specific antigenic peptide, thereby stabilizing the MHC class I molecule.

[0092] Natural class I MHC molecules bind peptides of diverse sequences with specific affinity. This can be achieved by the use of conserved amino acids at the ends of the peptide-binding groove that form pockets (typically the A and F pockets of the MHC-binding groove) that facilitate peptide binding. These binding pockets determine a set of requirements for antigenic peptide binding, typically referred to as anchor motifs (typically positions 2 or 3 and the c-terminal position of the peptide). Although natural MHC class I molecules bind many different antigenic peptides by recognition of the anchor motifs, each allele binds with high affinity only to a different subset of all available antigenic peptides. However, because the artificially introduced disulfide bridges of stabilized MHC class I molecules mimic the conformational and dynamic effects of bound specific antigenic peptides, aAPC scaffolds as described herein can be produced with empty MHC class I molecules that can bind a wide variety of antigenic peptides. This is further emphasized by the finding that T cell interactions based on disulfide bridges of stabilized MHC class I molecules are fully identical to those obtained with wild-type MHC molecules.

[0093] Thus, the aAPC scaffold is constructed from a polymer backbone coupled with a coupling agent to which affinity-tagged, disulfide-stabilized empty MHC class I molecules are attached. The empty MHC class I molecules can be loaded with antigenic peptides to form pMHC molecules that can direct specific interactions with specific T cells. In combination with co-attached affinity-tagged molecules that affect T cells, such as cytokines and costimulatory molecules, the aAPC scaffold stimulates specific T cells to achieve enhanced functional properties. Thus, the present invention shows the specific conditions required to expand tumor-reactive T cells by using MHC-loaded aAPC scaffolds to provide specific functional stimulation to cells to obtain ideal phenotypic and functional properties to mediate tumor regression or viral clearance. The aAPC scaffolds after loading of antigenic peptides into the empty MHC class I molecules can specifically interact with T cells based on the recognition of pMHC molecules, and through this specific interaction, effectively expand and functionally stimulate specific T cells in a peptide-MHC targeted manner.

[0094] The aAPC scaffold can be assembled by a combination of a variety of different template molecules (i.e., MHC class I molecules, molecules that influence T cells). The aAPC scaffolds described herein can include one or more costimulatory molecules, including, but not limited to, B7.1, B7.2, ICOS, PD-L1, a-galactosylceramide, CD3, CD4, CD5, CD8, CD9, CD27, CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM), CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), Fas (CD95), CD40, CD48, CD70, and CD72.

[0095] Additionally, the aAPC scaffolds described herein can be used to treat or inhibit any of the following cell types: interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-16 (IL-16), interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-19 (IL-20), interleukin-21 (IL-21), interleukin-22 (IL-22), interleukin-23 (IL-23), interleukin-24 (IL-24), interleukin-25 (IL-25), interleukin-26 (IL-26), interleukin-27 (IL-27), interleukin-28 (IL-28), interleukin-29 (IL-29), interleukin-30 (IL-30), interleukin-31 (IL-31), interleukin-32 (IL-32), interleukin-33 (IL-33), interleukin-34 (IL-34), interleukin-35 (IL-35), interleukin-36 (IL-36), interleukin-37 (IL-37), interleukin-38 (IL-38), interleukin-39 (IL-39), interleukin-39 (IL-39), interleukin-39 (IL-39), interleukin-39 (IL-39), interleukin-39 (IL The cytokines may include one or more cytokines including interleukin-17 (IL-17), interleukin-21 (IL-21), interleukin-22 (IL-22), interleukin-23 (IL-23), interferon alpha (IFN-α), interferon beta (IFN-β), interferon gamma (IFN-γ), IGIF, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF-α), tumor necrosis factor beta (TNF-β), and macrophage colony-stimulating factor (M-CSF), and variants and fragments thereof.

[0096] Herein, we describe an aAPC scaffold that, when loaded with antigenic peptides, is suitable for T cell proliferation and ensures a high proportion of active T cells, high antigen specificity of T cells and high functionality of T cells. Thus, a first aspect of the invention is an artificial antigen presenting cell (aAPC) scaffold comprising the following template molecule: i. a molecule that affects at least one T cell, and ii. at least one MHC class I molecule wherein the polymer backbone has attached thereto The MHC class I molecule comprises a heavy chain comprising an alpha-1 domain and an alpha-2 domain connected by a disulfide bridge, Concerning artificial antigen presenting cell (aAPC) scaffolds.

[0097] The disulfide bridge formed between the α-1 and α-2 domains is artificially introduced into the MHC class I molecule. Specifically, two mutated cysteine ​​residues are introduced into the amino acid sequence of the heavy chain to allow disulfide bridge formation between the α-1 and α-2 domains. The introduction of the mutated cysteine ​​residues can be carried out by any type of suitable mutagenesis, such techniques being known to those skilled in the art. Preferably, the positions of the mutagenesis are selected such that the resulting mutated cysteine ​​residues located in the α-1 and α-2 domains are within a spatial distance from each other that allows the formation of disulfide bridges under normal protein folding conditions.

[0098] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the disulfide bridge is formed between a mutated cysteine ​​residue located in the alpha-1 domain and a mutated cysteine ​​residue located in the alpha-2 domain.

[0099] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the spatial distance between the mutated cysteine ​​residue located in the alpha-1 domain and the mutated cysteine ​​residue located in the alpha-2 domain is 2 to 10 Å, for example 2 to 8 Å, preferably 2 to 5 Å.

[0100] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: Heavy chain: a. SEQ ID NO:1, or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). comprising an amino acid sequence selected from the amino acid sequence comprises a mutated cysteine ​​chain residue located in the alpha-1 domain and a mutated cysteine ​​residue located in the alpha-2 domain; Regarding the aAPC scaffold.

[0101] Yet another embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO:1, or b. comprising or consisting of an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a); The present invention relates to an aAPC scaffold, wherein the amino acid sequence comprises a mutated cysteine ​​residue located in the alpha-1 domain and a mutated cysteine ​​residue located in the alpha-2 domain.

[0102] Preferred mutations of the two cysteine ​​residues include modification of the amino acid at position 139 and either amino acid at position 84 or 85. The amino acid at position 139 is located in the alpha-2 domain of the heavy chain and is often an alanine residue. The amino acid at position 84 or 85 is located in the alpha-1 domain of the heavy chain and is often a tyrosine residue. Cysteine ​​mutations can be introduced by amino acid substitution by modification of the gene sequence of the heavy chain using standard genetic engineering.

[0103] Thus, a preferred embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the mutated cysteine ​​residue in the alpha-1 domain is at amino acid residue 84 or 85 and the mutated cysteine ​​residue located in the alpha-2 domain is at amino acid residue 139.

[0104] Upon folding of the MHC class I molecule, a disulfide bridge is formed between Cys-84 or Cys-85 and Cys-139. The newly formed disulfide bridge stabilizes the MHC class I molecule so that it remains stable in solution even in the absence of antigenic peptide. These stable empty MHC class I molecules can then be attached to the polymer backbone of the aAPC scaffold via the interaction between the affinity tag and the coupling agent.

[0105] The introduction of cysteine ​​mutant residues can be applied to any kind of MHC class I or MHC class I-like molecule.Accordingly, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the MHC class I molecule is selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MIC A, MIC B, CD1d, ULBP-1, ULBP-2, and ULBP-3.

[0106] The aAPC scaffold as described herein is also applicable for use with the murine MHC, referred to as the H-2 complex, and therefore an embodiment of the invention relates to an aAPC scaffold as described herein, wherein the heavy chain is an H-2 molecule, e.g., H-2Kb or H-2Db. Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO: 12 or SEQ ID NO: 13; or b. An amino acid sequence that has at least 80% sequence identity with any one of the sequences in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0107] Preferred variants of MHC class I molecules include HLA-A, HLA-B and H-2, each containing two mutated cysteine ​​residues. Accordingly, an embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. Any one of SEQ ID NOs: 2 to 13, or b. An amino acid sequence that has at least 80% sequence identity with any one of the sequences in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0108] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. Any one of SEQ ID NOs: 2 to 13, or b. an amino acid sequence having at least 80% sequence identity to any one of the sequences in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of the sequences in (a). The present invention relates to an aAPC scaffold comprising or consisting of an amino acid sequence selected from the following:

[0109] The term "SEQ ID NO:2 to 13" is understood to mean "SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13."

[0110] A further embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. Any one of SEQ ID NOs: 2 to 11, or b. An amino acid sequence that has at least 80% sequence identity with any one of the sequences in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0111] Yet another embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. Any one of SEQ ID NOs: 2 to 6; or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0112] The HLA allele commonly utilized for T cell expansion is the HLA-A 02:01 allele. Thus, a preferred embodiment of the invention is an aAPC scaffold as described herein, comprising a heavy chain: a. SEQ ID NO:2, or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0113] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO:2, or b. an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a). The present invention relates to an aAPC scaffold comprising or consisting of an amino acid sequence selected from the following:

[0114] The MHC class I molecule is attached to the polymer backbone of the aAPC scaffold by interaction between an affinity tag and a coupling agent. Preferably, the affinity tag, e.g., biotin, is located on the MHC class I molecule. Attachment of biotin to the heavy chain can be achieved by including a handle for biotinylation of the heavy chain, e.g., an Avi-tag. Thus, an embodiment of the present invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. Any one of SEQ ID NOs: 2 to 13, or b. an amino acid sequence having at least 80% sequence identity to any one of the sequences in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of the sequences in (a). or consisting of an amino acid sequence selected from the heavy chain further comprises SEQ ID NO: 19; Regarding the aAPC scaffold.

[0115] A preferred embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO: 14, or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0116] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO: 14, or b. an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a). The present invention relates to an aAPC scaffold comprising or consisting of the amino acid sequence:

[0117] A further embodiment of the invention is an aAPC scaffold as described herein, wherein the heavy chain is: a. SEQ ID NO: 17, or b. an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a). The present invention relates to an aAPC scaffold comprising or consisting of the amino acid sequence:

[0118] The heavy chain binds to a β2-microglobulin molecule (B2M) to form an MHC class I molecule. Specifically, the α-3 domain of the heavy chain is located adjacent to B2M. Thus, an embodiment of the invention relates to an aAPC scaffold as described herein, wherein at least one MHC class I molecule comprises a β2-microglobulin molecule.

[0119] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the β2-microglobulin molecule is: a. SEQ ID NO: 15, or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0120] The MHC class I molecule can also be provided as a finalized fusion protein with B2M connected to the heavy chain via a linker. Thus, an embodiment of the invention is an aAPC scaffold as described herein, wherein at least one MHC class I molecule is: a. SEQ ID NO: 16, or b. An amino acid sequence having at least 80% sequence identity with the sequence in (a). The present invention relates to an aAPC scaffold comprising an amino acid sequence selected from the group consisting of:

[0121] Another embodiment of the invention is an aAPC scaffold as described herein, wherein at least one MHC class I molecule is: a. SEQ ID NO: 16, or b. an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a). The present invention relates to an aAPC scaffold comprising or consisting of an amino acid sequence selected from the following:

[0122] A further embodiment of the invention is an aAPC scaffold as described herein, wherein at least one MHC class I molecule is: a. SEQ ID NO: 18, or b. an amino acid sequence having at least 80% sequence identity to the sequence in (a), e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence in (a). The present invention relates to an aAPC scaffold comprising or consisting of an amino acid sequence selected from the following:

[0123] The proliferation of some T cells can be enhanced when several T cell-influencing molecules are simultaneously present. The advantage achieved can be a synergistic effect of T cell-influencing molecules serving different purposes (e.g. growth, differentiation, activation, etc.) in the proliferation and stimulation of T cells. Thus, the T cell-influencing molecules can belong to the same or different classes of molecules. Thus, an embodiment of the present application relates to an aAPC scaffold as described herein, comprising at least two different T cell-influencing molecules.

[0124] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the molecule that affects T cells is selected from the group consisting of a cytokine, a costimulatory molecule, an adhesion molecule, and an antibody.

[0125] A preferred class of molecules that influence T cells are cytokines. Cytokines regulate the balance between humoral and cell-based immune responses, and they regulate the maturation, growth, and responsiveness of T cell populations. Some cytokines enhance or inhibit the action of other cytokines in complex ways, making the interactions between cytokine selection unpredictable. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the molecules that influence T cells are cytokines.

[0126] The cytokines described herein encompass both natural cytokines and mutants or mimetics of cytokines engineered to induce enhanced T cell activation and function. Thus, mutants or mimetics of cytokines such as interleukins may induce T cell activation and function corresponding to one or more cytokines. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, in which the molecule that influences T cells is a cytokine, or a mutant and mimetics thereof. Another embodiment of the present invention relates to an aAPC scaffold as described herein, in which the cytokine is selected from natural cytokines, or a mutant and mimetics thereof. A further embodiment of the present invention relates to an aAPC scaffold as described herein, in which the mutant or mimetics of cytokines induce T cell stimulation corresponding to one or more interleukins selected from the group of IL-2, IL-15, and IL-21. A further embodiment of the invention relates to an aAPC scaffold as described herein, wherein the cytokine variant or mimetic induces T cell stimulation in response to two interleukins selected from the group of IL-2, IL-15 and IL-21, e.g., IL-2 / IL-15, e.g., IL-2 / IL-21, or e.g., IL-15 / IL-21.

[0127] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cytokine is selected from the group consisting of IL-21, IL-2, IL-15, IL-1, IL-4, IL-6, IL-7, IL-9, IL-10, IL-12, IL-17, IL-22, and IL-23.

[0128] IL-2 is used therapeutically to regulate the strength of immune responses. IL-2 delivers its message by simultaneously binding to two receptor subunits known as IL-2 receptor beta and IL-2 receptor gamma (IL-2Rβ and IL-2Rγ), which form a heterodimeric signaling protein called IL-2Rβγc. A third non-signaling receptor called IL-2Rα (also known as CD25) contributes to the formation of the signaling complex and enhances the binding between IL-2 and IL-2Rβγc by approximately 100-fold.

[0129] Further embodiments of the invention relate to an aAPC scaffold as described herein, wherein the cytokine comprises at least IL-2, or variants and mimetics thereof. Further embodiments of the invention relate to an aAPC scaffold as described herein, wherein the cytokine consists of IL-2, or variants and mimetics thereof.

[0130] A variant or mimic of IL-2 is termed neoleukin-2 / 15. Neoleukin-2 / 15 (Neo-2 / 15) is a designer cytokine that is highly stable and binds strongly to IL-2Rβγc but not to CD25. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cytokine comprises at least Neo-2 / 15. Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cytokine consists of Neo-2 / 15.

[0131] Various cytokine groups have been identified to produce particularly favorable aAPC scaffolds. Without being bound by theory, one effective group of cytokines are those that deliver their intracellular signals through shared gamma chain receptors and affect T cell activation and differentiation. In this context, these cytokines are referred to as "gamma chain receptor cytokines". Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cytokine is a gamma chain receptor cytokine.

[0132] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is selected from the group consisting of IL-21, IL-2, IL-15, IL-4, IL-7 and IL-9.

[0133] The present inventors have identified preferred combinations of stimulatory molecules within the gamma chain receptor cytokine family.

[0134] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is selected from the group consisting of IL-21, IL-2 and IL-15.

[0135] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine comprises at least IL-21.

[0136] As outlined above, the interactions between some molecules affecting T cells, hereafter referred to as cytokines, can have beneficial effects that T cell proliferation can benefit from. This is also true for the gamma chain receptor cytokine group. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the aAPC scaffold comprises at least two gamma chain receptor cytokines.

[0137] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is: i. at least IL-2 and IL-21, or ii. at least IL-15 and IL-21 The present invention relates to an aAPC scaffold comprising:

[0138] A further embodiment of the invention is an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is: i. IL-2 and IL-21, or ii.IL-15 and IL-21 , regarding the aAPC scaffold.

[0139] Another embodiment of the invention is an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is: i. at least IL-4 and IL-21; ii. at least IL-7 and IL-21, or iii. At least IL-9 and IL-21 The present invention relates to an aAPC scaffold comprising:

[0140] Yet another embodiment of the invention is an aAPC scaffold as described herein, wherein the gamma chain receptor cytokine is: i. IL-4 and IL-21, ii. IL-7 and IL-21, or iii.IL-9 and IL-21 , regarding the aAPC scaffold.

[0141] Another type of T cell-influencing molecule that may be included in the aAPC scaffold is a costimulatory molecule that enhances T cell responses, proliferation, production and / or secretion of cytokines, stimulates T cell differentiation and effector functions, or promotes T cell survival. Thus, costimulatory molecules act in nature and in conjunction with the aAPC scaffold to induce T cell proliferation and differentiation alone and to enhance the effects of other T cell-influencing molecules, such as cytokines. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the T cell-influencing molecule comprises at least one costimulatory molecule.

[0142] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the costimulatory molecule is selected from the group consisting of B7.2 (CD86), B7.1 (CD80), CD40, ICOS and PD-L1.

[0143] The template molecule can be attached to the polymer backbone through the interaction between the coupling agent and the affinity tag. The coupling agent can be located on the polymer backbone of the aAPC scaffold and can be attached to the backbone through, but not limited to, hydrophobic interactions, electrostatic interactions, or covalent bonds. When located on the polymer backbone, the coupling agent provides a flexible template onto which affinity-tagged template molecules can be fixed in a modular manner. The affinity tag is a molecular species that specifically binds to the coupling agent through, but not limited to, non-covalent interactions. By attaching an affinity tag to each template molecule, it is easy to assemble a custom aAPC scaffold.

[0144] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein a template molecule is attached to the polymer backbone by non-covalent interactions between a coupling agent located on the polymer backbone and an affinity tag on the template molecule.

[0145] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the template molecule is attached to the polymer backbone by non-covalent interactions between a coupling agent located on the template molecule and an affinity tag on the polymer backbone.

[0146] Many known compatible pairs of affinity tags and coupling agents can be used in the present invention, including, but not limited to, biotin / streptavidin, biotin / avidin, biotin / neutravidin, biotin / strep-tactin, poly-His / metal ion chelate, peptide / antibody, glutathione-S-transferase / glutathione, epitope / antibody, maltose binding protein / amylase, and maltose binding protein / maltose. Other known compatible pairs of affinity tags and coupling agents can also be used in the present invention.

[0147] Accordingly, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the coupling agent / affinity tag is selected from the group consisting of biotin / streptavidin, biotin / avidin, biotin / neutravidin, biotin / strep-tactin, poly-His / metal ion chelate, peptide / antibody, glutathione-S-transferase / glutathione, epitope / antibody, maltose binding protein / amylase and maltose binding protein / maltose.

[0148] Another preferred embodiment of the invention relates to an aAPC scaffold as described herein, wherein the coupling agent is streptavidin and the affinity tag is biotin.

[0149] The polymer backbone of the aAPC scaffold with the attached template molecules can also be based on a variety of different materials. Thus, several types of backbones can be used in the present invention, including but not limited to polysaccharides, synthetic polysaccharides, vinyl polymers, polyethylene glycol, polypropylene glycol, derivatized cellulosic materials, strep-tactin and poly-streptavidin. The polysaccharides can be dextran or different variants of dextran, such as carboxymethyl dextran, dextran polyaldehyde, and cyclodextrin. An example of a synthetic polysaccharide is, for example, ficoll. Vinyl polymers include, but are not limited to, poly(acrylic acid), poly(acrylamide), poly(acrylic ester), poly(methyl methacrylate), poly(maleic acid), poly(acrylamide), poly(methacrylic acid) and poly(vinyl alcohol). Polymer backbones made of derivatized cellulosic materials include, but are not limited to, derivatized cellulose materials, including carboxymethyl cellulose, carboxymethyl hydroxyethyl cellulose and hydroxy-ethyl cellulose.

[0150] Additionally, there are commercially available polymer scaffolds that can serve as a basis for forming the self-assembling aAPC scaffolds of the present invention, including but not limited to Streptamers from IBA GmbH and Beckman Coulter, which are based on the Strep-tactin protein that oligomerizes to form multimers that can bind several biotinylated molecules, such as biotinylated MHC complexes and molecules that affect T cells, such as cytokines and costimulatory molecules.

[0151] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the polymer backbone is selected from the group consisting of polysaccharides, vinyl polymers, polyethylene glycol, polypropylene glycol, strept-tactin and poly-streptavidin.

[0152] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the polymer backbone is a polysaccharide.

[0153] A further preferred embodiment of the invention relates to an aAPC scaffold as described herein, wherein the polysaccharide is dextran.

[0154] The size of the polymer backbone sets a physical limit to how many template molecules can be attached to each aAPC scaffold: the size of the polymer backbone is given by its molecular weight.

[0155] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the dextran has a molecular weight in the range of 50-3000 kDa, such as 100-2500 kDa, for example 250-2500 kDa.

[0156] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the dextran has a molecular weight selected from the group consisting of 250 kDa, 270 kDa, 750 kDa, and 2000 kDa.

[0157] In addition to the number of molecules attached to each aAPC scaffold, another important parameter is the density with which the template molecules are distributed on the polymer backbone. The density can be changed by adjusting the ratio between all the molecules contained in the aAPC scaffold. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the polymer backbone:MHC class I molecules:costimulatory molecules:cytokines is selected from the group consisting of 1:1:1:1, 1:2:1:1, 1:4:1:1, 1:4:2:1, 1:4:2:2, 1:10:5:5, 1:4:4:4, 1:8:8:8, 1:10:10:10, 1:20:20:20, 1:30:30:30, 1:40:40:40, 1:50:50:50, 1:50:10:10 or 1:50:20:20.

[0158] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the ratio between polymer backbone:MHC class I molecule:cytokine 1:cytokine 2 is selected from the group consisting of 1:1:1:1, 1:2:1:1, 1:4:1:1, 1:4:2:1, 1:4:2:2, 1:10:5:5, 1:4:4:4, 1:8:8:8, 1:10:10:10, 1:20:20:20, 1:30:30:30, 1:40:40:40, 1:50:50:50, 1:50:10:10 or 1:50:20:20.

[0159] Yet another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the ratio between polymer backbone:MHC class I molecule:costimulatory molecule:cytokine 1:cytokine 2 is selected from the group consisting of 1:1:1:1:1, 1:2:1:1:1, 1:4:1:1:1, 1:4:2:1:1, 1:4:2:2:2, 1:10:5:5:5, 1:4:4:4:4, 1:8:8:8:8, 1:10:10:10:10, 1:20:20:20:20, 1:30:30:30:30, 1:40:40:40:40, 1:50:50:50:50, 1:50:10:10:10 or 1:50:20:20:20.

[0160] The present invention may be suitable for expanding T cells from a variety of subjects. Accordingly, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein at least one MHC class I molecule is a vertebrate MHC molecule, such as a human, murine, rat, porcine, bovine or avian molecule.

[0161] Another preferred embodiment of the invention relates to an aAPC scaffold as described herein, wherein the vertebrate MHC class I molecule is a human molecule.

[0162] As mentioned above, MHC molecules exist in several variants. MHC molecules include, but are not limited to, MHC class I molecules and MHC class I-like molecules. MHC class I-like molecules include, but are not limited to, CD1a, CD1b, CD1c, CD1d, MICA, MICB, MR1, ULBP-1, ULBP-2, and ULBP-3.

[0163] A preferred embodiment of the present invention relates to an aAPC scaffold as described herein, wherein at least one MHC class I molecule is a human MHC class I molecule. In humans, the major histocompatibility complex (MHC) is encoded by a complex of genes called the human leukocyte antigen (HLA) complex. The HLAs corresponding to MHC class I are called HLA-A, HLA-B and HLA-C. Thus, another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein at least one MHC class I molecule is selected from the group consisting of HLA-A, HLA-B and HLA-C.

[0164] The aAPC scaffolds described herein comprise MHC class I molecules stabilized by disulfide bridges connecting the alpha-1 and alpha-2 domains. While this allows for the formation of aAPC scaffolds with MHC class I molecules that do not contain antigenic peptides, the aAPC scaffolds can be provided with or without antigen-loaded MHC class I molecules. Even with unloaded MHC class I molecules, the ultimate intended use of the aAPC scaffolds includes loading antigenic peptides, thereby forming pMHC molecules.

[0165] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the MHC class I molecule comprises a peptide binding groove that is free of an antigenic peptide.

[0166] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the MHC class I molecule comprises a peptide-binding groove (pMHC) that contains an antigenic peptide.

[0167] The antigenic peptides presented by the pMHC molecules ultimately determine which type of T cells are expanded by the aAPC scaffold, a concept referred to above as MHC restriction. Antigenic peptides suitable for use in the aAPC scaffolds of the present invention can be derived from essentially any source. Antigenic sources can include, but are not limited to, human, viral, bacterial, parasitic, plant, fungal, or tumor. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the antigenic peptide of the pMHC is derived from a source selected from the group consisting of human, viral, bacterial, parasitic, plant, fungal, and tumor.

[0168] One use of the aAPC scaffold of the invention is in the expansion of tumor-reactive T cells for use in adoptive cell transfer (ACT). The strength of the ACT strategy is that the T cells are presented ex vivo in an environment optimal for efficient expansion of antigen-specific T cell populations, as opposed to the local tumor environment.

[0169] Another potential use of the aAPC scaffold of the present invention is for the expansion of T cell populations specific for fighting certain infections that typically occur as a result of transplantation. Transplanted patients typically undergo immunosuppressive therapy to avoid graft rejection. Often, such treatments leave patients vulnerable to aggressive viral strains, causing severe infections in already weakened patients. The aAPC scaffold of the present invention is highly suitable for the effective expansion of T cells extracted from transplanted patients for the purpose of treating severe infections by ACT strategies.

[0170] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the antigenic peptide of the pMHC is a cancer-associated epitope or a viral epitope.

[0171] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the antigenic peptide of the pMHC is a neoepitope, e.g., a cancer neoepitope or a cancer neoantigen.

[0172] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cancer associated epitope is a viral epitope associated with virally induced cancer.

[0173] Yet another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the cancer associated epitope is an overexpressed antigen associated with cancer.

[0174] A further embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cancer-associated epitope is a cancer-testis antigen.

[0175] The aAPC scaffolds of the invention function with any antigenic peptide that can be presented by a pMHC molecule attached to the polymer backbone. Several indications are preferred in the present invention.

[0176] Thus, a preferred embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the viral epitope is a virus selected from the group consisting of human papilloma virus (HPV), Merkel cell polyoma virus (MCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza virus.

[0177] To optimize the efficiency of each aAPC scaffold with respect to the precision with which it can propagate a single T cell specificity, in one version of the invention, each aAPC scaffold carries only a single variant of an MHC class I molecule, e.g., with the intention of intentionally loading only one antigenic peptide for each type of aAPC scaffold.

[0178] Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the aAPC scaffold comprises identical MHC class I molecules.

[0179] By presenting only a single antigenic peptide for each aAPC scaffold, competition between T cells of different specificities is limited to a minimum. If necessary, several different scaffolds presenting different peptides can be pooled together and grown simultaneously. Simultaneous growth of T cells with various different specificities is possible because competition between T cells is kept to a minimum due to the aAPC scaffold clustering all template molecules (i.e., pMHC and molecules that influence T cells) in close proximity to each other. Thus, T cells expanded by use of the aAPC scaffold of the present invention retain their specificity, and the pool of different specificities ensures the breadth of any immune response when reintroduced into the subject. This latter property is clinically important to avoid immune escape mutants. The breadth of the response can be adjusted by determining how many different aAPC scaffolds are pooled together in a single growth.

[0180] The polymer backbone may contain any number of MHC class I molecules that is reasonable given the size of the polymer backbone. Thus, embodiments of the present invention relate to aAPC scaffolds as described herein, wherein each polymer backbone contains at least 5 MHC class I molecules, such as at least 8, such as at least 10, such as at least 20, such as at least 30, such as at least 40, such as at least 50 or such as at least 100 MHC class I molecules.

[0181] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein each polymer backbone comprises at least two MHC class I molecules, e.g., at least three or, e.g., at least four MHC class I molecules.

[0182] For some applications, it may be practical to immobilize the aAPC scaffold on a solid support, e.g., for certain types of analysis or for separation of the aAPC scaffold from a proliferating T cell population. Thus, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the aAPC scaffold is immobilized on a solid support.

[0183] Another embodiment of the invention relates to a solid support to which template molecules as described herein are directly attached, thus in this particular case the template molecules are not located on the polymer backbone of the aAPC scaffold.

[0184] Many variations of solid supports exist and can be selected depending on the application of the aAPC scaffold, including but not limited to beads, well plates, particles, filters, gels, tubes, and petri dishes.

[0185] Accordingly, an embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the solid support is selected from the group consisting of beads, well plates, particles, filters, gels, tubes, and Petri dishes.

[0186] The aAPC scaffold can be attached to the solid support by any conventional means, eg, a linker, antibody, or the like.

[0187] Many different template molecules exist and therefore a wide variety of aAPC scaffolds can be assembled. The inventors have found that certain combinations of template molecules result in particularly efficient and preferred aAPC scaffolds.

[0188] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. the gamma chain receptor cytokines are IL-15 and IL-21; iii. Regarding an aAPC scaffold, wherein the costimulatory molecule is B7.2 (CD86).

[0189] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the MHC class I molecules, IL-15, IL-21 and B7.2 (CD86) on the dextran backbone is 2:1:1:1.

[0190] Yet another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, the MHC class I molecule, IL-15, IL-21 and B7.2 (CD86) is 1:10:5:5:5.

[0191] A further embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the gamma chain receptor cytokines are IL-2, IL-15 and IL-21.

[0192] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran, and ii. For an aAPC scaffold, wherein the gamma chain receptor cytokines are IL-21, IL-2 and IL-15.

[0193] An embodiment of the invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, MHC class I molecule, IL-2, IL-15 and IL-21 is 1:10:5:5:5.

[0194] Yet another embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. the gamma chain receptor cytokines are IL-2, IL-15, and IL-21; and iii. Regarding an aAPC scaffold, wherein the costimulatory molecule is B7.2 (CD86).

[0195] Another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, MHC class I molecule, IL-2, IL-15, IL-21 and B7.2 (CD86) is 1:10:5:5:5:5.

[0196] A preferred embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran, and ii. The aAPC scaffold, wherein the gamma chain receptor cytokines are IL-2 and IL-21, or IL-15 and IL-21.

[0197] Yet another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the cytokines comprise at least IL-6 and IL-10.

[0198] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. the costimulatory molecule is B7.2 (CD86); iii. The aAPC scaffold, wherein the cytokines are IL-6 and IL-10.

[0199] A further embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the MHC class I molecules, IL-6, IL-10 and B7.2 (CD86) on the dextran backbone is 2:1:1:1.

[0200] A further embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, the MHC class I molecule, IL-6, IL-10 and B7.2 (CD86) is 1:10:5:5:5.

[0201] An embodiment of the invention relates to an aAPC scaffold as described herein, wherein the gamma chain receptor cytokines include at least IL-2 and IL-21.

[0202] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. For aAPC scaffolds, wherein the gamma chain receptor cytokines are IL-2 and IL-21.

[0203] Yet another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between MHC class I molecules, IL-2 and IL-21 on the dextran backbone is 1:1:1.

[0204] Another embodiment of the invention relates to an aAPC scaffold as described herein, wherein the costimulatory molecules include at least B7.2 (CD86).

[0205] Yet another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, the MHC class I molecule, the IL-2 and the IL-21 is 1:8:8:8.

[0206] A further embodiment of the invention relates to an aAPC scaffold as described herein, wherein the polymer backbone comprises at least IL-1 and PD-L1.

[0207] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. the costimulatory molecules are B7.2 (CD86) and PD-L1; iii. The aAPC scaffold, wherein the cytokine is IL-1.

[0208] A further embodiment of the invention relates to an aAPC scaffold as described herein, wherein the ratio between MHC class I molecules, IL-1, B7.2 (CD86) and PD-L1 on the dextran backbone is 2:1:1:1.

[0209] Yet another embodiment of the present invention relates to an aAPC scaffold as described herein, wherein the ratio between the dextran backbone, the MHC class I molecule, IL-1, B7.2 (CD86) and PD-L1 is 1:10:5:5:5.

[0210] Yet another embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. the costimulatory molecules are B7.2 (CD86) and ICOS; iii. The aAPC scaffold, wherein the cytokine is IL-10.

[0211] Yet another embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. Regarding an aAPC scaffold, wherein the cytokines are IL-1 and IL-2.

[0212] A further embodiment of the invention is an aAPC scaffold as described herein, comprising: i. the polymer backbone is dextran; ii. The aAPC scaffold, wherein the cytokines are IL-2 and IL-15.

[0213] The aAPC scaffold of the present invention may be part of a kit suitable for use by a hospital or laboratory. Such a kit may contain one or more different aAPC scaffolds suitable for expanding T cells with different specificities, as well as a medium suitable for expanding T cells extracted from a sample. The kit may also hold other compounds or molecules necessary for the expansion of a T cell-containing sample.

[0214] Thus, an embodiment of the present invention is a kit for expanding T cells comprising: i. a first storage means comprising at least one aAPC scaffold as described herein; and ii. A second storage means for at least one antigenic peptide. Including, The kit is adapted for combining the contents of the first storage means and the second storage means.

[0215] An embodiment of the present invention relates to a kit as described herein, wherein the second storage means comprises a library of antigenic peptides. The library of antigenic peptides may comprise a selection of the most frequently used antigenic peptides.

[0216] The aAPC scaffolds of the invention can be used as immunotherapies for administration directly to a subject to support the subject's immune system. The aAPCs can be administered either locally or systemically by any route, for example, intravenously, intraperitoneally, intramuscularly, subcutaneously, transdermally, or orally.

[0217] The aAPC scaffold as described herein can be utilized as part of an automated system for T cell expansion and / or adoptive T cell (ACT) therapy. The aAPC scaffold can thus be a component of an apparatus or system, for example, for the production of T cells for clinical use. Thus, embodiments of the present invention relate to an apparatus or system for T cell expansion and / or adoptive T cell (ACT) therapy that includes an aAPC scaffold as described herein. The aAPC scaffold can be used for cell production in combination with various forms of fluorescence activated cell sorting or similar cell selection strategies.

[0218] Methods for T cell expansion By extracting immune-reactive T cells from unhealthy subjects, expanding the T cells ex vivo, and reintroducing the expanded T cell population into the subject, it is possible to overcome some of the challenges of immunosuppressive diseases that would otherwise paralyze the immune system. However, while it is no problem to extract T cells from peripheral blood, for example by apheresis procedures, and then reintroduce them into the patient, the activation and expansion of T cells of a given specificity remains a major challenge, and in many cases the resulting T cell population lacks sufficient differentiation and functional capacity.

[0219] The aAPC scaffolds of the invention are suitable for simultaneous in vitro stimulation and expansion of T cells, producing T cell populations with high proportions of active T cells, highly antigen-specific T cells and highly functional T cells. Accordingly, another aspect of the invention is a method for simultaneous in vitro stimulation and expansion of T cells, comprising the following steps: Providing a sample comprising iT cells; ii. contacting the sample with a proliferation solution comprising an aAPC scaffold as described herein; iii. stimulating and expanding T cells with specificity for the aAPC scaffold; iv. harvesting the T cells of step iii) from the culture to obtain an expanded antigen-specific population of T cells; The present invention relates to a method comprising the steps of:

[0220] An embodiment of the present invention provides a method for simultaneous in vitro stimulation and expansion of T cells, comprising the following steps: i. providing an aAPC scaffold as described herein, wherein the MHC class I molecule comprises a peptide binding groove that does not contain an antigenic peptide; ii. mixing the aAPC scaffold with an antigenic peptide to provide a loaded aAPC scaffold containing pMHC molecules; iii. Providing a sample comprising T cells; iv. contacting the sample with the loaded aAPC scaffold of step ii); v. stimulating and expanding T cells with specificity for the loaded aAPC scaffold in culture; vi. harvesting the T cells of step iii) from the culture to obtain an expanded antigen-specific population of T cells; The present invention relates to a method comprising the steps of:

[0221] A sample containing T cells is extracted from a subject and then placed in a culture containing an aAPC scaffold under conditions that allow the growth of T cells. It should therefore be understood that the expansion of T cells is carried out in a solution or medium that contains, in addition to the aAPC scaffold, all the compounds and factors necessary for cell growth. Thus, the culture in which T cell expansion is carried out may contain compounds that inhibit the growth of unrelated cells or promote the growth of T cells, for example, IL-2.

[0222] To improve the quality of the expanded T cell population, the aAPC scaffold can be filtered by centrifugation through a molecular weight cutoff filter to remove all unbound pMHC molecules, and then the aAPC can be mixed with the sample. This can avoid stimulation from pMHC molecules that are not bound to the scaffold, and can also remove excess antigen peptides and molecules that affect T cells, limiting the stimulation of irrelevant T cell subsets. The same applies to antigen peptides that are not complexed with MHC molecules, which can also be removed by centrifugation through a molecular weight cutoff filter.

[0223] Thus, embodiments of the present invention relate to methods as described herein, wherein the growth solution is filtered prior to contacting with the sample.

[0224] Another embodiment of the invention relates to a method as described herein, wherein the growth solution is filtered by centrifugation through a molecular weight cut-off filter.

[0225] The advantage of the aAPC scaffolds of the present invention is that they allow the simultaneous proliferation of different T cell specificities, since cross-reactivity is reduced to a minimum as explained above when using multiple different aAPC scaffolds. The method of the present invention is therefore also effective for samples containing various T cells with different specificities.

[0226] Thus, an embodiment of the present invention relates to a method as described herein, wherein said sample in step i) comprises T cells of at least 2 different specificities, such as at least 5 different specificities, such as at least 10 different specificities, such as at least 15 different specificities, such as at least 20 different specificities, or such as at least 50 different specificities.

[0227] Another embodiment of the invention relates to a method as described herein, wherein said solution comprising aAPC scaffolds comprises at least 2 different aAPC scaffolds, such as at least 5 different aAPC scaffolds, such as at least 10 different aAPC scaffolds, such as at least 15 different aAPC scaffolds, such as at least 20 different aAPC scaffolds, or such as at least 20 different aAPC scaffolds.

[0228] Yet another embodiment of the invention relates to a method as described herein, wherein T cells of at least two different specificities are stimulated and expanded in parallel, e.g. in the same sample with at least 5 different specificities, such as at least 10 different specificities, such as at least 15 different specificities, or e.g. at least 20 different specificities.

[0229] A further embodiment of the present invention is a method as described herein, comprising the steps of: i. providing a sample comprising T cells with at least five different specificities; ii. contacting the sample with a proliferation solution comprising at least five different aAPC scaffolds; iii. Parallel stimulation and expansion of said T cells with at least five different specificities for said at least five different aAPC scaffolds in culture; iv. harvesting the T cells of step iii) from the culture to obtain an expanded antigen-specific population of T cells having at least five different specificities; The present invention relates to a method comprising the steps of:

[0230] The sample containing the T cells to be expanded may come from any source, but is typically extracted from blood, tissue or bodily fluid. Accordingly, embodiments of the present invention relate to methods as described herein, wherein the sample is selected from the group consisting of peripheral blood mononuclear cells, tumor, tissue, bone marrow, biopsy, serum, blood, plasma, saliva, lymphatic fluid, pleural fluid, cerebrospinal fluid and synovial fluid.

[0231] The sample comprising T cells to be expanded according to the methods described herein can also be selected from stem cells or TCR-modified / transduced cells.

[0232] The methods of the invention can be used to expand any T cell that expresses a TCR required for interaction with a pMHC molecule on an aAPC scaffold. Thus, T cells suitable for expansion by the methods of the invention include, but are not limited to, CD8 T cells, CD4 T cells, regulatory T cells, natural killer T (NKT) cells, alpha-beta T cells, gamma-delta T cells, NK cells, mucosal-associated invariant T (MAIT) cells, and lymphokine-activated killer (LAK) cells.

[0233] T cell receptor (TCR) gene therapy allows targeting of optimal predetermined cancer antigen peptides without relying on the prior existence of tumor-reactive T cells. This approach is based on the observation that antigen specificity can be transferred between T cells by introducing genes encoding the TCR α- and β-chains that together form the αβ-TCR heterodimer. Thus, the introduction of genes encoding tumor-reactive TCRs can be used to redirect patient-derived cells (autologous) or non-patient-derived (xenogeneic) cells to the antigen of interest, thereby establishing a tumor-reactive T cell compartment that would not otherwise exist. Several TCR optical therapeutic approaches have now shown clinical activity in solid tumors. Most of these TCR therapeutic approaches rely on ex vivo expansion of TCR-transduced cells. These cells can be autologous or xenogeneic T cells, NK cells, MAIT cells or NKT cells. Because cancer-specific TCR genes are transduced into cells, they do not rely on the prior existence of TCRs and therefore do not necessarily have to be T cells.

[0234] Accordingly, an embodiment of the invention relates to a method as described herein, wherein the T cells are selected from the group consisting of CD8 T cells, CD4 T cells, regulatory T cells, natural killer T (NKT) cells, gamma-delta T cells, NK cells and innate mucosal-associated invariant T (MAIT) cells.

[0235] A preferred embodiment of the invention relates to a method as described herein, wherein the T cells are CD8 T cells.

[0236] Yet another embodiment of the invention relates to a method as described herein, wherein the T cell is a CAR T cell.

[0237] For the reintroduction of the expanded T cell population into the patient to be meaningful from a therapeutic perspective, it is necessary that the extracted T cells are expanded to clinically relevant numbers. T cell expansion by the method of the present invention can be on the order of 100-3000 fold. The number of cells available before reintroduction into the patient can be as high as 10 per dose. 5 ~10 12 Cells, e.g., 10 per dose 5 ~10 10 Cells, e.g., 10 per dose 6 ~10 9 Cells are administered in volumes ranging from 20 mL to 1 L depending on the route of administration.

[0238] Accordingly, embodiments of the present invention relate to methods as described herein for expanding T cells to clinically relevant numbers.

[0239] As described above for the aAPC scaffold, the MHC class I molecules can present a variety of antigenic peptides. The same applies to the method as for the selection of the antigenic peptide. Thus, an embodiment of the present invention relates to a method as described herein, wherein the antigenic peptide of the pMHC is a cancer-associated epitope or a viral epitope.

[0240] Another embodiment of the invention relates to a method as described herein, wherein the antigenic peptide comprises a cancer-associated epitope or a viral epitope.

[0241] Another embodiment of the present invention relates to a method as described herein, wherein the cancer associated epitope is a viral epitope associated with a virally induced cancer.

[0242] Yet another embodiment of the invention relates to the method as described, wherein the viral epitope is derived from a virus selected from the group consisting of human papilloma virus (HPV), Merkel cell polyoma virus (MCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza virus.

[0243] Use of expanded T cell populations It is envisioned that the expanded T cell population obtained by the method of the present invention can be effectively used in a treatment regimen focused on adoptive immunotherapy (or adoptive cell transfer). In such a treatment regimen, immune-reactive T cells from a subject in need of treatment are extracted. The subject can be any mammal, for example, human, bovine, porcine, avian, canine, feline, mouse, rat, etc. The source of T cells can be, for example, peripheral blood mononuclear cells, tumor, tissue, bone marrow, biopsy, serum, blood, plasma, saliva, lymphatic fluid, pleural fluid, cerebrospinal fluid, or synovial fluid.

[0244] Once extracted from the subject, the sample containing T cells of the desired specificity or specificities is expanded using an aAPC scaffold customized for the subject and the condition or disease being treated. This expansion is carried out according to the methods of the invention as described above. Once the T cell population has expanded to clinically relevant numbers, it is administered to the subject to induce an immune response and treat the disease.

[0245] Consequently, an aspect of the present invention relates to an expanded T cell population obtained by the methods as described herein.

[0246] The T cell population expanded on the aAPC scaffold disclosed herein has several favorable properties, such as a high fraction of antigen-specific cells, a multi-cytokine secretion profile, a young phenotype and less exhaustion. The multi-cytokine secretion profile can be characterized by simultaneous secretion of INF-γ and TNF-α, and cytotoxic degranulation. The young phenotype can be characterized by high expression of activators, such as CD28. The reduced exhaustion can be characterized by low expression of inhibitors, such as PD1. Thus, an embodiment of the invention is an expanded T cell population obtained by the method as described herein, wherein the expanded T cell population: i. antigen-specific T cells are expanded at least 10-fold after 2 weeks of culture; ii. secretion of INF-γ and TNF-α upon subsequent antigen challenge; iii. high expression of CD28, and iv. Low expression of PD1 The present invention relates to an expanded T cell population having at least one, such as at least two, such as at least three, characteristics selected from the group consisting of:

[0247] Another embodiment of the invention is an expanded T cell population obtained by the method as described herein, wherein the expanded T cell population has the following characteristics: i. antigen-specific T cells expand at least 10-fold after 2 weeks of culture; and ii. Secretion of INF-γ and TNF-α upon subsequent antigen challenge The present invention relates to an expanded T cell population, comprising:

[0248] A further embodiment of the invention is an expanded T cell population obtained by the method as described herein, wherein the expanded T cell population has the following characteristics: i. antigen-specific T cells are expanded at least 10-fold after 2 weeks of culture; ii. Secretion of INF-γ and TNF-α upon subsequent antigen challenge iii. high expression of CD28, and iv. Low expression of PD1 The present invention relates to an expanded T cell population, comprising:

[0249] A further embodiment of the present invention relates to an expanded T cell population obtained by a method as described herein, wherein after 2 weeks of culture the antigen-specific T cells are expanded at least 10-fold, such as at least 25-fold, such as at least 50-fold, such as at least 100-fold, such as at least 1000-fold, such as at least 5000-fold.

[0250] Yet another embodiment of the present invention relates to an expanded T cell population obtained by the method described herein, wherein the antigen-specific T cells after two weeks of culture have expanded in the range of 10-fold to 5000-fold, for example 100-fold to 1000-fold.

[0251] A further embodiment of the invention relates to an expanded T cell population obtained by a method as described herein, wherein high expression of CD28 is defined as at least a two-fold increased expression of CD28, such as at least a five-fold increased expression, such as at least a ten-fold increased expression, compared to CD28 expression of non-proliferating non-specific T cells in the sample.

[0252] Another embodiment of the invention relates to an expanded T cell population obtained by a method as described herein, wherein low expression of PD1 is defined as at most half (50%) expression of PD1, such as at most one quarter (25%) expression, such as at most one tenth (10%) expression, compared to non-expanded non-specific T cells in the sample.

[0253] A fourth aspect of the invention relates to an expanded T cell population obtained by a method as described herein, for use as a medicament.

[0254] More specifically, embodiments of the present invention provide a method for adoptive immunotherapy of a disease or disorder, comprising: i. extracting a sample comprising T cells from a subject; ii. contacting the sample with a proliferation solution comprising an aAPC scaffold as described herein; iii. stimulating and expanding T cells having specificity for the aAPC scaffold in culture; iv. harvesting the T cells of step iii) from the culture to obtain an expanded antigen-specific population of T cells; and The expanded antigen-specific population of vT cells is administered to the subject in an amount effective to induce an immune response. The present invention relates to a method comprising the steps of:

[0255] As described above for the aAPC scaffold, MHC class I molecules can present a variety of antigenic peptides. The same considerations regarding the selection of antigenic peptides apply for the use of the expanded T cell populations obtained by the methods of the invention.

[0256] Thus, another aspect of the present invention relates to an expanded T cell population obtained by a method as described herein for use in the treatment of cancer or viral disease.

[0257] An embodiment of the invention relates to an expanded T cell population for use as described herein, wherein the cancer is associated with a viral disease.

[0258] Another embodiment of the invention relates to an expanded T cell population for use as described herein, wherein the viral disease is associated with a virus selected from the group consisting of human papilloma virus (HPV), Merkel cell polyoma virus (MCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza virus.

[0259] The expanded T cell populations obtained by the methods as described herein can be formulated into pharmaceutical compositions further comprising one or more adjuvants and / or excipients and / or pharma- ceutically acceptable carriers, including, but not limited to, buffers, suspending agents, dispersing agents, solubilizing agents, pH adjusting agents, and / or preservatives.

[0260] The pharmaceutical compositions can be used in adoptive immunotherapy (or adoptive cell transfer) for administration either locally or systemically by any route, e.g., intravenously, intraperitoneally, intramuscularly, subcutaneously, transdermally or orally.

[0261] It should be noted that embodiments and features described in the context of one of the aspects of the invention also apply to the other aspects of the invention.

[0262] All patent and non-patent literature cited in this application is incorporated herein by reference in its entirety.

[0263] The invention is further described in the following non-limiting examples. EXAMPLES

[0264] Example 1: Expansion of antigen-specific CD8 T cells using antigen-presenting scaffolds (Figure 2) HLA-A1 FLU BP-VSD (VSDGGPNLY (SEQ ID NO: 29))-specific CD8 T cells from healthy donors were expanded in parallel in the presence of either antigen-presenting scaffolds in a ratio of 1:10:5:5:5 (scaffold:pMHC:B7-2:IL-15:IL-21), free FLU BP-VSD peptide (SEQ ID NO: 29), IL-15, and IL-21 cytokines, or antigen-presenting scaffolds in a ratio of 1:10:5:5:5 with irrelevant peptide specificity in the MHC complex. aAPC scaffolds were prepared with wild-type MHC. All cultures were supplemented with 20 IU / ML IL-2 and cultured for 2 weeks. The proliferation of HLA-A1 FLU BP-VSD-specific CD8 T cells was followed by tetramer staining once a week. Representative dot plots are shown in Figure 2.

[0265] Conclusion: (Figure 2A-D) This experiment shows that it is possible to expand antigen-specific CD8 T cells with a low-frequency baseline response in a pMHC-directed manner using antigen-presenting scaffolds. When comparing the proliferation of cells stimulated with peptide, IL-15 and IL-21 freely added in the culture medium, and cells stimulated with antigen-presenting scaffolds, it is clear that cells stimulated with antigen-presenting scaffolds expanded the most in both frequency and absolute number of specific CD8 T cells (see Figure 2E-F). Furthermore, antigen-presenting scaffolds with irrelevant peptide MHC specificity are unable to stimulate A1 FLU BP-VSD-specific CD8 T cell proliferation, indicating that cells cannot benefit from co-attached cytokines and costimulatory molecules without established pMHC-directed interactions.

[0266] Example 2: Assembly of artificial antigen-presenting cell (aAPC) scaffolds for production of Cys-mutated MHC (antigen / peptide receptive) and specific T cell expansion Here we describe a method to create an aAPC scaffold by coupling molecules that affect MHC complexes and T cells, such as cytokines and stimulatory molecules, to dextran via streptavidin-biotin interactions. In this example, both MHC and disulfide-stabilized Cys-mutated MHC were prepared and used for the assembly of the aAPC scaffold. In principle, biotin-streptavidin can be replaced with any dimerization domain, with half of the dimerization domain being coupled to the MHC complex or the molecule that affects T cells, and the other half being coupled to a dextran or similar scaffold backbone.

[0267] Streptavidin modified dextran is commercially available in a variety of dextran sizes, for example, MW 250KDa, 750KDa, 2000KDa from Fina Biosolutions, and approximately 270KDa dextran from Immudex.

[0268] Both wt MHC and Cys-mutated MHC were produced by classical E. coli expression, exemplified here with the heavy chain of wt HLA-A 02:01 with an Avi-tag (SEQ ID NO: 17) and the heavy chain of Cys-mutated HLA-A 02:01 with an Avi-tag (SEQ ID NO: 14), respectively. Briefly, both wt MHC and MHC Cys-mutated proteins, as well as the light chain beta-2 microglobulin (B2M) protein, were produced in E. coli using pET series plasmids. Inclusion bodies containing E. coli-produced proteins were collected by sonication, lysing E. coli cells in lysis buffer (Tris-Cl 50 mM, pH 8.0, 1 mM EDTA, 25% sucrose). The soluble fraction of denatured protein was collected from the inclusion bodies by washing in detergent buffer (Tris-Cl 20 mM, pH 7.5, 200 mM NaCl, 2 mM EDTA, NP40 1%, deoxycholate 1%) and wash buffer (0.5% Triton X-100, 1 mM EDTA), followed by incubation in resolubilization buffer (HEPES 50 mM, pH 6.5, 8 M urea, 0.1 mM β-mercaptoethanol) at 4°C for 48 h and storage at -80°C until use for MHC class I monomer production.

[0269] Cys-mutated MHC monomers were generated by in vitro folding of Cys-mutated MHC proteins and B2M in the presence of helper molecules, e.g., dipeptides / tripeptides / small molecules (folding buffer: 100 mM Tris-Cl, pH 8.0, 400 mM L-arginine, 2 mM EDTA, and protease inhibitor cocktail). wt MHC was generated like Cys-mutated MHC monomers, except that no helper molecules were included. Instead, wt MHC molecules were refolded in the presence of UV-labile peptide KILGFVF-XV (SEQ ID NO: 24), where X refers to 3-amino-2-(2-nitrophenyl)propionic acid, an amino acid sensitive to ultraviolet light, which cleaves the full-length peptide upon exposure to UV light. The resulting reduced binding affinity of the cleaved peptide fragments to the MHC molecule allows binding of the incoming exchange antigen peptide.

[0270] MHC monomers were purified by conventional size exclusion chromatography. Alternatively, other standard protein purification methods can be used. Purification of Cys-mutated MHC monomers by size exclusion chromatography can be performed using buffers with or without MHC monomer stabilizing helper molecules, such as the dipeptide glycine-leucine.

[0271] Such produced stable Cys-mutated MHC monomers without antigenic peptide (empty MHC monomer) are very useful for rapid generation of large number of antigenic peptide loaded MHC monomers for various research, diagnostic and therapeutic uses. Antigenic peptide loaded Cys-mutated MHC (pMHC) monomers can be prepared by incubating 100 μM peptide with 200 μg / mL Cys-mutated empty MHC monomer for 30-60 min at room temperature. Wt pMHC can be produced from MHC monomers containing UV labile peptide by including 200 μM of antigen-peptide of choice and then exposing the monomer to 360 nm UV light for 1 h.

[0272] pMHC and molecules that affect T cells, such as cytokines and costimulatory molecules, can be biotinylated by both standard chemical and enzymatic protocols. For example, pMHC can be enzymatically biotinylated by including a biotinylation consensus peptide sequence in the MHC heavy chain, allowing site-specific biotinylation using BirA enzyme and free biotin. Cytokines and costimulatory molecules are commercially available from suppliers such as BioLegend and PreProtech. These proteins are easily biotinylated by using commercially available biotinylation reagents such as EZ-Link Sulfo-NHS-LC-Biotin from ThermoFisher Scientific and reacting according to the supplier's protocol.

[0273] In the examples described herein, the aAPC scaffold was assembled via streptavidin-biotin interaction. Briefly, the biotinylated molecules bound by dextran and streptavidin were combined in an aqueous buffer such as PBS in a relative stoichiometry according to the examples described below to obtain a final concentration of 60 nM assembled aAPC scaffold. The aAPC scaffold was allowed to assemble at 4°C for 1 hour and then kept at 4°C until added to the cell culture. The assembled scaffold can be stored at 4°C for at least 1 month. The assembled aAPC scaffold can be purified and separated from unbound antigen peptides, pMHC, cytokines and costimulatory molecules by centrifuging the unbound molecules through a MW cutoff filter such as Amicon Ultra Centrifugal Filter Unit Ultra-4, MWCO 100 kDa.

[0274] T cell cultures were established from human PBMCs or TILs and cultured at 2 × 10 6Cells were initiated at 100 cells / ml and cultured for 2 weeks at 37°C and 5% CO2. Cells were stimulated twice weekly by adding aAPC scaffolds at a final concentration of 0.2 nM in 1 mL of fresh X-VIVO15 medium supplemented with 5% heat-inactivated human serum. After 1 week of culture, cells were transferred to 24-well flat-bottom culture dishes and samples were taken from the cultures once a week for MHC tetramer staining to track the proliferation of antigen-specific CD8 T cells by flow cytometry.

[0275] Example 3: Expansion of antigen-specific CD8 T cells using aAPC scaffolds prepared with Cys-mutated MHC monomers and their functional evaluation compared to aAPC scaffolds prepared with wild-type MHC monomers (Figures 3-4)

[0276] Here we describe the assembly of aAPC scaffolds using Cys-mutated MHC class I HLA-A*02:01 monomers against FLU 58-66 GILGFVFTL (SEQ ID NO: 20) and EBV BMF1 GLCTLVAML (SEQ ID NO: 21) and the specific CD8 T cell expansion from healthy donor PBMCs using these aAPC scaffolds. Comparative functional evaluation is performed with respect to aAPC scaffolds prepared from wild-type MHC class I HLA-A*02:01 monomers. Data are shown in Figures 3 and 4.

[0277] Cys-mutated HLA-A*02:01 monomers were prepared as described in Example 2. Briefly, the heavy chain construct containing the Cys-mutated HLA-A*02:01 DNA sequence (SEQ ID NO: 14) and the wild-type human B2M (SEQ ID NO: 15) construct were transformed into E. Coli expression strain pLysS to produce these proteins. The inclusion bodies containing the expressed proteins were collected by standard procedures using sonication in lysis buffer, followed by washing in detergent buffer and washing buffer, and the proteins were solubilized in urea buffer for 48 hours at 4°C to collect the denatured soluble fraction of the proteins. A similar procedure was performed to produce the soluble denatured proteins of wild-type HLA-A 02:01.

[0278] The denatured soluble fraction of Cys-mutated HLA-A*02:01 was folded to produce monomers of Cys-mutated HLA-A*02:01. The heavy chain protein of Cys-mutated HLA-A*02:01 and B2M were mixed in a 1:2 molar ratio in a folding buffer containing 100 mM Tris-Cl, pH 8.0, 400 mM L-arginine, and 2 mM EDTA in the presence of the dipeptide glycine-leucine (GL). After folding, the monomers were biotinylated with the Avi-tag sequence incorporated into the heavy chain using a biotin-protein ligase enzymatic reaction at 30° C. for 1 h according to the protocol from Avi-tag. These biotinylated monomers of Cys-mutated HLA-A*02:01 were purified by size-exclusion chromatography (HPLC, Waters Corporation, USA). Since the folding reaction did not contain HLA-A*02:01-specific antigen peptide, the Cys-mutated HLA-A*02:01 monomer is empty and peptide-receptive. After purification, the quality assessment of the Cys-mutated HLA-A*02:01 monomer was performed for protein concentration and biotinylation, and it was stored at -80°C until further use.

[0279] Wild-type HLA-A*02:01 monomers were prepared by a process similar to that described above, but in the presence of a UV-labile HLA-A*02:01-specific peptide (SEQ ID NO: 24), which is essential for the folding and stability of wild-type MHC. Thus, purified, biotinylated wild-type HLA-A*02:01 monomers are always in a form associated with this peptide.

[0280] To assemble aAPC scaffolds with Cys-mutated HLA-A02:01 specific for FLU 58-66 GILGFVFTL (SEQ ID NO:20) or EBV BMF1 GLCTLVAML (SEQ ID NO:21), 100 μM peptide of each specificity, diluted in PBS, was mixed with 100 μg / mL Cys-mutated HLA-A02:01 monomer for 60 min in a 20 μL reaction in PBS. In parallel, the cytokines IL-2 and IL-21 were assembled on the dextrans scaffolds at a molar ratio of 1:8:8 by incubating IL-2 and IL-21 with the dextrans scaffolds for 30 min. To these assembled cytokine dextrans scaffolds, antigen-specific Cys-mutated HLA-A*02:01 monomers were added to a molar ratio of 1:8 and incubated for 30 min to generate antigen-presenting scaffolds with a scaffold, pMHC, IL-2, IL-21 ratio of 1:8:8:8. Any possible free streptavidin sites on the scaffold were blocked by adding 20 μM D-biotin and incubating for 20 min.

[0281] Because wild-type HLA-A*02:01 monomers were bound to the pre-bound peptide, aAPC scaffolds using wild-type HLA-A02:01 specific for FLU 58-66 GILGFVFTL (SEQ ID NO: 20) or EBV BMF1 GLCTLVAML (SEQ ID NO: 21) required an additional step to exchange the pre-bound peptide with the FLU 58-66 GILGFVFTL or EBV BMF1 GLCTLVAML specific peptide. 100 μg / ml of wild-type HLA-A*02::01 monomers were mixed with 200 μM of antigen peptide in PBS to a total volume of 20 μL and incubated under a UV lamp (366 nm) for 60 min to promote exchange of the pre-bound UV-labile peptide with the antigen specific peptide. After the reaction, aAPC scaffolds were assembled as described above for Cys-mutated aAPC scaffolds using wild-type HLA-A*02:01 monomers and cytokines at a molar ratio of 1:8:8:8 (scaffold:pMHC:IL-2:IL-21). Scaffolds were stored at 4° C. until use for T cell expansion.

[0282] To evaluate and compare aAPC scaffolds prepared with Cys-mutated and wild-type HLA-A*02:01 molecules specific for FLU 58-66 GILGFVFTL and EBV BMF1 GLCTLVAML, parallel cultures with these two scaffolds were established with PBMCs from two different healthy donors corresponding to each specificity. Alongside the scaffolds of the positive specificities, negative control scaffolds made with an irrelevant peptide (HLA-A*02:01 HIV Pol ILKEPVHGV (SEQ ID NO: 23)) were also included. All aAPC scaffold-based T cell expansion was performed in 48-well flat-bottom cell culture plates in X-vivo medium supplemented with 5% human serum at 2 × 10 per specificity. 6PBMCs were used to initiate. 3 μl of aAPC scaffold of each specificity was added every 2 or 3 days 4 times and cultures were maintained for 2 weeks. 10 samples were collected and tested for proliferation using intracellular cytokine staining induced by antigen-specific stimulation. Expanded cells of each specificity were loaded with 5 μM of the relevant antigen peptide at a cell concentration of 300.000 cells / 100 μL in X-vivo medium supplemented with 5% human serum. After incubation with antigen peptide, expanded cells were washed and stained first with the relevant cell surface antibodies (CD3, CD4, CD8 and viable dyes), followed by intracellular staining for TNFα (PE-Cy7) and IFNγ (APC) using cell permeabilization buffer. Cells were fixed and analyzed on a flow cytometer.

[0283] In the present specification, examples using two antigen peptides are shown. However, the present invention is not limited to a limited set of antigen peptides. Other related peptides include, but are not limited to, SEQ ID NOs: 25 to 28.

[0284] Conclusion: (Figures 3 and 4) This experiment shows that it is possible to expand antigen-specific CD8+ T cells with low frequency baseline responses in a pMHC-directed manner using aAPC scaffolds presenting FLU58-66GILGFVFTL (Figure 1) and EBV BMF1GLCTLVAML (Figure 2) antigens using Cys-mutated variants of the HLA-A*02:01 protein. This example shows that it is possible to use Cys-mutated MHC for rapid production and antigen diversification of the aAPC scaffold for expansion of antigen-specific T cells.

[0285] CD8 T cells expanded using Cys-mutated MHC aAPC scaffolds were found to be functionally comparable to aAPC scaffolds prepared with wild-type MHC, as indicated by intracellular cytokine (TNFα and IFNγ) release by antigen peptide-specific expanded CD8 T cells against FLU 58-66 GILGFVFTL (Figure 1) and EBV BMF1 GLCTLVAML (Figure 2). Functional analysis also confirms that aAPC scaffolds with Cys-mutated MHC expand only antigen-specific cells, as no expansion of irrelevant peptide-specific CD8 T cells was observed.

[0286] In Example 1, it is shown that cells stimulated with aAPC scaffolds prepared with wt MHC molecules show superior proliferation in terms of frequency and absolute number of specific CD8 T cells compared to proliferation and stimulation using free antigen peptides and molecules that affect T cells. In this example, it is shown that Cys-mutated MHC aAPC scaffolds proliferate and stimulate CD8 T cells with similar efficiency as aAPC scaffolds prepared with wt MHC molecules. As a result, Cys-mutated MHC aAPC scaffolds are superior to proliferation and stimulation using free antigen peptides and molecules that affect T cells.

[0287] Example 4: Assembly of an artificial antigen-presenting (aAPC) scaffold using disulfide-stabilized empty MHC class I and specific T cell proliferation using the aAPC (Figures 5-7) Here, we describe how aAPC scaffolds can be assembled using Cys-mutated MHC without antigen peptide. Such aAPC scaffolds are antigen peptide receptive and can therefore be produced in combination with personalized cancer immunotherapy, where cancer peptide antigens are identified prior to antigen identification, for example, from complete tumor sequencing. aAPC scaffolds can be assembled essentially as described in Examples 2 and 3, except that antigen peptides are loaded onto Cys-mutated MHC monomers after assembly of aAPC scaffolds (post-assembly), as opposed to loading onto MHC before assembly of aAPC scaffolds (pre-assembly).

[0288] These aAPC scaffolds with empty MHC molecules could be loaded with antigenic peptides of interest in a single step, thereby converting them into pMHC-specific aAPC scaffolds. Such antigen-receptive aAPC scaffolds eliminate the processing time to generate each pMHC-specific aAPC scaffold and limit batch-specific variation, since each pMHC aAPC scaffold is generated from a stable master batch of aAPC scaffolds with empty MHC molecules.

[0289] Described here is the use of such a loadable (post-assembled) aAPC scaffold to expand HLA-A*02:01 CMV pp65 NLVP MVATV (SEQ ID NO: 22)-specific CD8 T cells from healthy donor PBMCs. A comparison of the quantitative expansion efficiency of post-assembled aAPC scaffolds and aAPC scaffolds with preloaded antigen peptides (pre-assembled) using either Cys-mutated MHC and wild-type MHC molecules is shown in Figure 5. The functionality of these expanded CD8 T cells specific for HLA-A*02:01 CMV pp65 NLVP MVATV by post-assembled aAPC scaffolds, pre-assembled aAPC scaffolds with Cys-mutated MHC, and pre-assembled aAPC scaffolds with wild-type MHC was determined by measuring cytokine release (Figure 6).

[0290] To further establish a general proof of concept, validation of CD8+ T cell expansion using post-assembled aAPC scaffolds was performed by proliferation and functional evaluation of HLA-A*02:01 EBV BMF1 GLCTLVAML (SEQ ID NO:21)-specific CD8+ T cells from different healthy donor PBMCs. Results were compared to proliferation with pre-assembled aAPC scaffolds with Cys-mutated MHC and with wild-type MHC (Figure 7).

[0291] To assemble empty aAPC scaffolds, Cys-mutated MHC class I monomers were produced as described in Example 2, except that they were not immediately loaded with antigenic peptides. These biotinylated empty MHC monomers, cytokines, and costimulatory molecules were assembled on streptavidin-modified dextran via streptavidin-biotin interactions to generate antigen-receptive aAPC scaffolds bearing empty MHC class I molecules.

[0292] The process of assembling empty aAPC scaffolds with Cys-mutated HLA-A*02:01 molecules was carried out as follows: Dextran scaffold backbone was first incubated with biotinylated IL-2 and IL-21 at a molar ratio of 1:8:8 for 30 min at 4° C. in PBS buffer. Then, 100 μg / mL of Cys-mutated MHC (empty) monomer was added and incubated at 4° C. for 30 min to generate a post-assembly loadable aAPC scaffold at a molar ratio of 1:8:8:8 (scaffold:Cys-mutated MHC:IL-2:IL-21). Any remaining empty streptavidin binding sites on the dextran backbone were blocked by adding 20 μM D-biotin. Since these aAPC scaffolds do not contain antigen specificity, large batches of these loadable aAPC scaffolds of HLA-A*02:01 were stored at 4° C. until further use.

[0293] The HLA-A*02:01 post-assembly loadable aAPC scaffold was then evaluated to expand HLA-A*02:01 CMV pp65 NLVPMVATV (SEQ ID NO: 22)-specific CD8 T cells from healthy donor PBMCs. On the day of initiating the expansion culture, the HLA-A*02:01 empty aAPC scaffold was converted to an HLA-A*02:01 CMV pp65 NLVPMVATV-specific aAPC scaffold by adding antigen peptide directly to the empty aAPC scaffold. Briefly, 100 μM of peptide diluted in PBS was incubated with 20 μL of the empty aAPC scaffold and incubated for 30 minutes. Such aAPC scaffolds generated by converting the post-assembly loadable aAPC scaffold in a single step were then used to set up the expansion culture. 3 μL of specific aAPC scaffold was added to 2×10 6PBMCs were added and cultures were initiated in 48-well plates in X-vivo medium supplemented with 5% serum. Cultures were then maintained for 2 weeks with the addition of 3 μL of aAPC scaffold three more times over a 2-week period. In parallel, similar growth cultures of HLA-A*02:01 CMV pp65 NLVPMVATV specificity were initiated with preassembled aAPC scaffolds made from wild-type and Cys-mutated HLA-A*02:01 monomers. Growth cultures from this setup were used for comparative evaluation of the growth efficiency of loadable aAPC scaffolds. After 10 days, samples were collected and CD8 T cell proliferation of each specificity was determined for each specificity using pMHC tetramers (Figure 5).

[0294] From these expanded cultures, another set of expanded cells was collected to assess functionality and compare across all three aAPC scaffolds (post-assembly loaded aAPC scaffolds with Cys-mutated MHC, pre-assembly loaded aAPC scaffolds with Cys-mutated MHC, and pre-assembly loaded aAPC scaffolds with wild-type MHC).

[0295] For functional evaluation, expanded cells were loaded with HLA-A*02:01 CMV pp65 NLVP MVATV antigen to induce and detect antigen-stimulated cytokines TNFα and IFNγ as markers of cytotoxic killing. CD8 T cells expressing these markers simultaneously are interpreted as having high killing capacity. Cells were loaded with 5 μM of relevant peptides for 2 h at a cell concentration of 300000 cells / 100 μL in X-vivo medium supplemented with 5% human serum. After incubation with antigen peptides, expanded cells were washed and stained first with relevant cell surface antibodies (CD3, CD4, CD8, and viable dyes), followed by intracellular staining for TNFα (PE-Cy7) and IFNγ (APC) using cell permeabilization buffer. Cells were fixed and analyzed by flow cytometer (Figure 6).

[0296] In further validation experiments for the assembly-loadable aAPC scaffold, HLA-A*02:01 EBV BMF1 GLCTLVAML (SEQ ID NO: 21)-specific CD8 T cells from different healthy donor PBMCs were expanded by using the assembly-loadable aAPC scaffold (1:8:8:8). These scaffolds were converted into antigen-specific pMHC scaffolds by adding 100 μM EBV BMF1 GLCTLVAML peptide to 20 μL of the loadable aAPC scaffold and incubated for 30 minutes to generate HLA-A*02:01 EBV BMF1 GLCTLVAML-specific aAPC scaffolds. HLA-A*02:01 EBV BMF1 GLCTLVAML-specific aAPC scaffolds using wild-type or Cys-mutated MHC molecules were generated as described in Example 2.

[0297] Expanded cultures specific for HLA-A*02:01 EBV BMF1 GLCTLVAML were initiated in 48-well plates using three aAPC scaffolds from healthy donor PBMCs and maintained in X-vivo medium supplemented with 5% human serum for 2 weeks with stimulation every 3 days with the relevant aAPC scaffold.

[0298] Functional evaluation of expanded CD8 T cells was performed after 10 days of expansion by collecting 300.000 cells for each specificity and measuring intracellular cytokine release after antigen peptide loading as described in Example 3. Briefly, expanded cells were loaded with 5 μM EBV BMF1 GLCTLVAML peptide for 2 h at a cell concentration of 300.000 cells / 100 μL in X-vivo medium supplemented with 5% human serum. After incubation with antigen peptide, expanded cells were washed and stained first with relevant cell surface antibodies (CD3, CD4, CD8 and viable dyes), followed by intracellular staining for TNFα (PE-Cy7) and IFNγ (APC) using cell permeabilization buffer. Cells were fixed and analyzed on a flow cytometer (Figure 7).

[0299] Conclusion: (Figures 5-7) This experiment shows that it is possible to expand antigen-specific CD8 T cells and low-frequency baseline responses using a post-assembly loadable aAPC scaffold that is converted into an antigen-specific aAPC scaffold in a single step of antigen peptide loading. Figure 5 shows the expansion efficiency of such a post-assembly loadable aAPC scaffold specific for HLA-A*02:01 CMV pp65 NLVPMVATV (SEQ ID NO: 22) CD8 T cells expanded from 0.18% of total CD8+ T cells at baseline (Figure 5A) to 25% of total CD8+ T cells (Figure 5B). The efficiency was comparable to pre-assembled aAPC scaffolds using both wild-type as well as Cys-mutated MHC molecules. The functionality of these expanded CD8 T cells, measured using antigen-specific cytokine release, was found to be comparable across all three variants (post-assembly loaded aAPC scaffold with Cys-mutated MHC, pre-assembly loaded aAPC scaffold with Cys-mutated MHC, and pre-assembly loaded aAPC with wild-type MHC) (FIG. 6). The results in FIG. 7 further establish the functionality of expanded CD8 T cells specific for HLA-A*02:01 EBV BMF1 GLCTLVAML (SEQ ID NO: 21) using post-assembly loadable aAPC scaffolds from different donor PBMCs. This indicates that post-assembly loadable aAPC scaffolds provide efficient T cell stimulation, activating polyfunctional T cells and thus providing a beneficial aAPC scaffold since they can be stored in a loadable form at 4° C. until use and converted to aAPC scaffolds of any specificity with a single step addition of antigen peptide.

[0300] Taken together, these examples demonstrate the feasibility of using empty Cys-mutated MHC for rapid generation and antigen diversification of aAPC scaffolds for the expansion of antigen-specific T cells, which is advantageous in the adoptive T cell transfer setting, where rapid expansion of patient-derived cancer-specific T cells is essential for effective clinical outcomes.

[0301] In the present specification, examples using two antigen peptides are given. However, the present invention is not limited to a limited set of antigen peptides. Other related peptides include, but are not limited to, SEQ ID NOs: 25-28.

[0302] Example 5: TCR recognition of disulfide-stabilized (Cys-mutant) pMHC tetramers In this example, we compared the ability of wt pMHC to recognize the TCR with the ability of Cys-mutated pMHC to recognize the same TCR. This was done to verify that Cys-mutated pMHC presents peptide antigens to the TCR in a manner similar to wt pMHC.

[0303] Briefly, pMHC tetramers were prepared from biotinylated wt pMHC monomers in combination with fluorochrome-conjugated streptavidin. Biotinylated pMHC monomers and Cys-mutated MHC monomers were prepared essentially as described in Example 2. Antigenic peptide-specific MHC tetramers (pMHC) using wt HLA-A*02:01 monomers were prepared as described in Example 4.

[0304] Briefly, wt HLA-A*02:01 monomers (pre-bound with UV-labile peptide KILGFVF-XV (SEQ ID NO: 24)) were exchanged with antigenic peptide by incubating 100 μg / mL of wt HLA-A02:01 monomers with 200 μM of antigenic peptide in PBS buffer in a reaction volume of 20 μL for 1 h under a UV lamp (366 nm wavelength). These exchanged antigenic peptide-specific monomers were then conjugated with fluorophore-labeled streptavidin to generate antigenic peptide-specific tetramers, each tetramer specificity was prepared with two different fluorophores to detect CD8 T cells of each specificity using two different colors for conformational analysis. pMHC tetramers using Cys-mutated MHC molecules were prepared by directly incubating 200 μM of antigenic peptide with 100 μg / mL of Cys-mutated MHC monomer in a reaction volume of 20 μL for 1 h, since there was no pre-bound antigenic peptide and therefore no exchange process was required. The antigenic peptide-specific Cys-mutated MHC monomers were then tetramerized by incubation with two different colored fluorophore-labeled streptavidins for each specificity.

[0305] For comparative analysis of TCR recognition, wt and Cys-mutant MHC tetramers were prepared against four different HLA-A*02:01 antigen specificities; EBV LMP2 FLYALALLL (SEQ ID NO: 26), FLU 58-66 GILGFVFTL (SEQ ID NO: 20), EBV LMP2 CLGGLLTMV (SEQ ID NO: 25), and EBV BMF1 GLCTLVAML (SEQ ID NO: 21). Using wt and Cys-mutant MHC tetramers, CD8+ T cells from healthy donors were detected and antigen peptide-specific T cells were assessed as a percentage of total CD8+ T cells (Figure 8).

[0306] Conclusion: This example shows that Cys-mutated MHC has the same ability to bind antigenic peptide-specific T cells as the wt MHC. Both forms of pMHC monomers can be converted into MHC tetramers and have been shown to elicit the same population of antigenic peptide-specific T cells equally efficiently.

[0307] Example 6: Functional capacity of aAPC scaffold-expanded T cells in cancer models In this example, we isolate human cancer-specific tumor infiltrating lymphocytes (TILs) from tumor material. TILs are expanded using aAPC scaffolds and tested for functional capacity in cancer models. T cells expanded on aAPC scaffolds are a benchmark for T cells expanded using state-of-the-art TIL expansion protocols with rapid expansion using high doses of IL-2.

[0308] The antitumor activity of aAPC scaffold-grown T cells is examined in a 3D microtumor model. Fresh melanoma tissue is processed within 24 hours after surgery. Tissue samples are washed, minced, and gently digested using a blend of collagenase enzymes. After this, the microtumor preparation is subsequently filtered through a cell strainer to separate 3D microtumors with a size greater than 50 μm. These 3D microtumors are grown under serum-free conditions. The antitumor reactivity of aPC scaffold-grown T cells is evaluated using a fluorescent dye-based cytotoxicity assay in co-culture with 3D microtumors established from the same patient. The cytotoxic response of 3D microtumor cells against autologous cell products (control) is evaluated over a period of up to 96 hours. In parallel with the cytotoxicity analysis described above, the extent of 3D microtumor invasion by each cell product is analyzed using hepatocyte 3D confocal fluorescence microscopy.

[0309] Conclusion: This example demonstrates that T cells expanded using the AAPC scaffold have anti-tumor reactivity against autologous cancer microtumors.

[0310] Example 7: In vivo antitumor activity of aAPC scaffold-expanded T cells in a humanized mouse model In this example, we demonstrate the in vivo antitumor activity of aAPC scaffold-expanded T cells in humanized huIL2-NOG mice, which has recently been reported to model and predict the clinical activity of adoptively transferred melanoma-derived TILs.

[0311] Briefly, tumors are implanted in NOD / SCID / IL2Rγ (NOG) mice. After engraftment, tumors are serially transplanted into 3-5 NOG mice or 3-5 human IL-2-transduced NOG mice (huIL2-NOG). huIL2-NOG mice are treated with aAPC-expanded T cells by tail vein injection. Tumor growth is compared between tumor-bearing mice treated with adoptive T cell transfer or untreated by caliper measurement or imaging (depending on tumor type). T cells expanded in mice are immunophenotyped and analyzed for inhibitory and stimulatory signals.

[0312] Conclusion: This example demonstrates that aAPC scaffold-expanded T cells have in vivo anti-tumor reactivity.

[0313] Example 8: Expansion of antigen-specific CD8 T cells using aAPC scaffolds bearing neoleukin-2 / 15 (Neo-2 / 15) This example describes the assembly of aAPC scaffolds bearing Neo-2 / 15 with wild-type MHC class I HLA-A*01:01 monomer against A1 CMV pp65 YSEHPTFTSQY (sequence number 30) and specific CD8 T cell expansion from healthy donor PBMCs using these aAPC scaffolds (Figure 9).

[0314] Wild-type HLA A*02:01 monomers were prepared by a process similar to that described in Example 2, but in the presence of the UV-labile HLA A*01:01-specific peptide STAPG-X-LEY (SEQ ID NO: 31), where X refers to the UV-sensitive amino acid 3-amino-2-(2-nitrophenyl)propionic acid, which cleaves the full-length peptide upon exposure to UV light and is essential for the folding and stability of wild-type MHC. Thus, purified and biotinylated wild-type HLA A*01:01 monomers are always in this peptide-bound form.

[0315] Since the aAPC scaffold with wild-type HLA-A*01:01 monomer was bound with pre-bound peptide, the aAPC scaffold using wild-type HLA-A*01:01 monomer of A1 CMV pp65 YSEHPTFTSQY required peptide exchange of pre-bound peptide with CMV pp65 YSEHPTFTSQY-specific peptide. 100 μg / ml of wild-type HLA-A*01:01 monomer was mixed with 200 μM of antigen peptide in PBS to a total volume of 20 μL and incubated under a UV lamp (366 nm) for 60 min to promote exchange of pre-bound UV-labile peptide with antigen-specific peptide. After the reaction, the aAPC scaffold was assembled using wild-type HLA-A*01:01 monomer and cytokines. The scaffold was stored at 4° C. until use for T cell expansion.

[0316] aAPC scaffold-based T cell expansion was performed in 48-well flat-bottom cell culture plates in X-vivo medium supplemented with 5% human serum at 2 × 10 cells per specificity. 6Cultures were initiated with PBMCs. 3 μl of aAPC scaffold was added 4 times every 2 or 3 days and the cultures were maintained for 2 weeks. 10 samples were collected and tested for proliferation using intracellular cytokines induced by antigen-specific stimulation. Expanded cells were loaded with 5 μM of the relevant antigen peptide for 2 hours at a cell concentration of 300.000 cells / 100 μL in X-vivo medium supplemented with 5% human serum. After incubation with the antigen peptide, expanded cells were washed and stained first with the relevant cell surface antibodies (CD3, CD4, CD8, and viable dyes), followed by intracellular staining for TNFα (PE-Cy7) and IFNγ (APC) using cell permeabilization buffer. Cells were then fixed and analyzed by flow cytometer.

[0317] Herein, an example using one antigen peptide is given. However, the present invention is not limited to a limited set of antigen peptides. Other related peptides include, but are not limited to, SEQ ID NOs: 25-28.

[0318] Conclusion: This experiment shows that it is possible to use an aAPC scaffold presenting Neo-2 / 15 in combination with HLA-A*01:01 CMV pp65YSEHPTFTSQY antigen to expand antigen-specific CD8 T cells in a pMHC-directed manner with a low frequency baseline response (Figure 9). This example shows that it is possible to use an aAPC scaffold presenting Neo-2 / 15 in combination with HLA-A*01:01 for the rapid generation of antigen-specific T cells.

[0319] CD8 T cells expanded on the Neo-2 / 15 aAPC scaffold were found to be functionally comparable to aAPC scaffolds prepared with IL-2, as indicated by intracellular cytokines (TNFα and IFNγ) released by antigen peptide-specific expanded CD8 T cells for the HLA-A*01:01 CMV pp65 YSEHPTFTSQY antigen (FIG. 9). Functional analysis also confirmed that the aAPC scaffolds with Neo-2 / 15 expanded only antigen-specific cells, as no expansion of irrelevant peptide-specific CD8 T cells was observed.

[0320] In Example 1, it is shown that cells stimulated with aAPC scaffolds prepared with MHC molecules show superior proliferation in terms of frequency and absolute number of specific CD8 T cells compared to proliferation and stimulation using free antigen peptides and molecules that affect T cells. In Example 3, it is shown that Cys-mutated MHC aAPC scaffolds proliferate and stimulate CD8 T cells with similar efficiency to aAPC scaffolds prepared with wt MHC molecules. In this example, it is shown that aAPC scaffolds with Neo-2 / 15 favorably proliferate and stimulate antigen-specific CD8 T cells.

[0321] References International Publication No. 2002072631 International Publication No. 2009003492 International Publication No. 2009094273 US Patent Application Publication No. 2011 / 318380 U.S. Patent No. 9,494,588

Claims

1. A template molecule of: i. at least two T cell influencer molecules selected from the group consisting of cytokines, costimulatory molecules, adhesion molecules, and antibodies; and ii. an artificial antigen presenting cell (aAPC) scaffold comprising a polymer backbone having at least one MHC class I molecule bound thereto, the MHC class I molecule comprises a heavy chain comprising an α-1 domain and an α-2 domain connected by a disulfide bridge; the MHC class I molecule is HLA-A, HLA-B, or HLA-C having a mutated cysteine ​​residue located in the alpha-1 domain and a mutated cysteine ​​residue located in the alpha-2 domain; The artificial antigen presenting cell (aAPC) scaffold, wherein the T cell effector molecules include IL-21 and IL-2.

2. 2. The artificial antigen presenting cell (aAPC) scaffold of claim 1, wherein the disulfide bridge is formed between the mutated cysteine ​​residue located in the alpha-1 domain and the mutated cysteine ​​residue located in the alpha-2 domain.

3. The artificial antigen presenting cell (aAPC) scaffold of claim 1 or 2, wherein the polymer backbone comprises at least five MHC class I molecules.

4. The artificial antigen presenting cell (aAPC) scaffold of any one of claims 1 to 3, wherein the T cell influencing molecule is a cytokine.

5. 5. The artificial antigen presenting cell (aAPC) scaffold of claim 4, wherein the cytokine is selected from the group consisting of IL-21, IL-2, IL-15, IL-1, IL-4, IL-6, IL-7, IL-9, IL-10, IL-12, IL-17, IL-22, and IL-23.

6. The artificial antigen presenting cell (aAPC) scaffold of claim 4 or 5, wherein the cytokine is a gamma chain receptor cytokine.

7. 7. The artificial antigen presenting cell (aAPC) scaffold of claim 6, wherein the gamma chain receptor cytokine is selected from the group consisting of IL-21, IL-2, IL-15, IL-4, IL-7 and IL-9.

8. The artificial antigen presenting cell (aAPC) scaffold of claim 6 or 7, wherein the gamma chain receptor cytokine is selected from the group consisting of IL-21, IL-2 and IL-15.

9. The artificial antigen presenting cell (aAPC) scaffold of any one of claims 1 to 8, wherein the MHC class I molecule comprises a peptide binding groove that is free of an antigenic peptide.

10. The artificial antigen presenting cell (aAPC) scaffold of any one of claims 1 to 8, wherein the MHC class I molecule comprises a peptide-binding groove (pMHC) that contains an antigenic peptide.

11. 1. A method for simultaneous in vitro stimulation and expansion of T cells, comprising the steps of: i. contacting a sample containing T cells with a proliferation solution comprising the artificial antigen presenting cell (aAPC) scaffold of claim 10; ii. stimulating and expanding T cells with specificity for the aAPC scaffold in culture; and iii. harvesting the T cells of step ii) from said culture to obtain an expanded antigen-specific population of T cells.

12. 1. A kit for expanding T cells comprising: i. a first storage means comprising at least one artificial antigen presenting cell (aAPC) scaffold according to any one of claims 1 to 9; ii. a second storage means comprising at least one antigenic peptide; Including, A kit, wherein the contents of the first storage means and the second storage means are adapted to be combined.

Citation Information

Patent Citations

  • Production of antigen-specific t-cells

    WO2017161092A1